㽶Ƶ

Skip to main content
Adam J. Gordon
No Rating Available
(Learn About Our Rating System)

Adam J. Gordon, MD, MPH, FACP, DFASAM

Languages spoken: English
  • Adam J. Gordon's professional mission is to improve the access and quality of care of patients who have vulnerabilities, including those with addiction disorders. He is the Elbert F. and Marie Christensen Endowed Research Professor, tenured Professor of Medicine and Psychiatry at the 㽶Ƶ of Utah School of Medicine, and the Section Chief of Addiction Medicine at the VA Salt Lake City Health Care System. He is a board-certified internal medicine and addiction medicine physician and is a Fellow in the American College of Physicians (FACP) and a Distinguished Fellow in the American Society of Addiction Medicine (DFASAM). He is the PI of the Greater Intermountain Node (GIN), a Center site of the NIH NIDA Clinical Trials Network; founded and is the Director of the Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA); and founded and is the Emeritus Director the Vulnerable Veteran Innovative Patient-Aligned-Care-Team (VIP) Initiative, a clinical-evaluation initiative at the VA Salt Lake City Health Care System. Adam J. Gordon is a Core Faculty member of the VA Salt Lake City Informatics, Decision-Enhancement and Analytic Sciences (IDEAS) Center, a Department of Veterans Affairs Health Services Research and Development (HSR&D) Center of Innovation (COIN). He is also the Editor-in-Chief of the journal Substance Abuse (impact factor 3.9).

    Adam J. Gordon has a 25-year track record of conducting research on the quality, equity, and efficiency of health care for vulnerable populations, including those who are homeless and those with substance use disorders. A major theme of his research includes examining the efficacy, effectiveness, and implementation of evidence-based identification, assessment, and treatments for patients with addiction. His methodological skills include health services, clinical trial, large database, and implementation science research. He has received efforts on over 100 federal peer reviewed grants from the NIH, VA, AHRQ, PCORI, and SAMHSA. He has authored over 310 peer reviewed articles (15.3% first authored, 27.2% senior authored, 40.8% authored with mentee) in high impact journals (e.g., JAMA, BMJ, Lancet; H-index=56) and presented/published hundreds of scholarly works. As evidence of how his research has impacted clinical care and my profession, he was awarded one of VA HSR&D’s highest honors by receipt of the 2021 VA Health Services Research and Development (HSR&D) “Health System Impact Award” and received the 2022 David C. Lewis, MD Service to Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) Award.

    He has mentored undergraduate, graduate, MD, and PhD trainees, VA and K- Career Development Awardees, and junior through tenured faculty. In addition, his post-doctoral mentees have received research Career Development Awards and have obtained large research awards. He is a primary or secondary mentor on over a dozen current or prior VA, NIH K-, or institutional K-awards. He has been honored locally and nationally for his mentorship abilities: named as an inaugural VA Health Services Research and Development National Mentor Network (MNet) mentor, received the “Allen Humphrey Excellence in Medical Student Research Mentoring Award” from the 㽶Ƶ of Pittsburgh School of Medicine, and was the recipient of the 2013 W. Anderson Spickard, Jr. Excellence in Mentorship Award from Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA). His time allocation (for a 60-hour work week between the 㽶Ƶ and the VA is 80% research/mentoring, 10% clinical/education, 10% administration).

    Board Certification

    American Board of Addiction Medicine
    American Board of Internal Medicine
    American Board of Preventive Medicine (Addiction Medicine)
  • Adam J. Gordon's professional mission is to improve the access and quality of care of patients who have vulnerabilities, including those with addiction disorders. He is the Elbert F. and Marie Christensen Endowed Research Professor, tenured Professor of Medicine and Psychiatry at the 㽶Ƶ of Utah School of Medicine, and the Section Chief of Addiction Medicine at the VA Salt Lake City Health Care System. He is a board-certified internal medicine and addiction medicine physician and is a Fellow in the American College of Physicians (FACP) and a Distinguished Fellow in the American Society of Addiction Medicine (DFASAM). He is the PI of the Greater Intermountain Node (GIN), a Center site of the NIH NIDA Clinical Trials Network; founded and is the Director of the Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA); and founded and is the Emeritus Director the Vulnerable Veteran Innovative Patient-Aligned-Care-Team (VIP) Initiative, a clinical-evaluation initiative at the VA Salt Lake City Health Care System. Adam J. Gordon is a Core Faculty member of the VA Salt Lake City Informatics, Decision-Enhancement and Analytic Sciences (IDEAS) Center, a Department of Veterans Affairs Health Services Research and Development (HSR&D) Center of Innovation (COIN). He is also the Editor-in-Chief of the journal Substance Abuse (impact factor 3.9).

    Adam J. Gordon has a 25-year track record of conducting research on the quality, equity, and efficiency of health care for vulnerable populations, including those who are homeless and those with substance use disorders. A major theme of his research includes examining the efficacy, effectiveness, and implementation of evidence-based identification, assessment, and treatments for patients with addiction. His methodological skills include health services, clinical trial, large database, and implementation science research. He has received efforts on over 100 federal peer reviewed grants from the NIH, VA, AHRQ, PCORI, and SAMHSA. He has authored over 310 peer reviewed articles (15.3% first authored, 27.2% senior authored, 40.8% authored with mentee) in high impact journals (e.g., JAMA, BMJ, Lancet; H-index=56) and presented/published hundreds of scholarly works. As evidence of how his research has impacted clinical care and my profession, he was awarded one of VA HSR&D’s highest honors by receipt of the 2021 VA Health Services Research and Development (HSR&D) “Health System Impact Award” and received the 2022 David C. Lewis, MD Service to Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) Award.

    He has mentored undergraduate, graduate, MD, and PhD trainees, VA and K- Career Development Awardees, and junior through tenured faculty. In addition, his post-doctoral mentees have received research Career Development Awards and have obtained large research awards. He is a primary or secondary mentor on over a dozen current or prior VA, NIH K-, or institutional K-awards. He has been honored locally and nationally for his mentorship abilities: named as an inaugural VA Health Services Research and Development National Mentor Network (MNet) mentor, received the “Allen Humphrey Excellence in Medical Student Research Mentoring Award” from the 㽶Ƶ of Pittsburgh School of Medicine, and was the recipient of the 2013 W. Anderson Spickard, Jr. Excellence in Mentorship Award from Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA). His time allocation (for a 60-hour work week between the 㽶Ƶ and the VA is 80% research/mentoring, 10% clinical/education, 10% administration).

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Psychiatry -Adjunct
    Academic Divisions Adult Psychiatry
    Epidemiology
    Board Certification
    American Board of Addiction Medicine
    American Board of Internal Medicine
    American Board of Preventive Medicine (Addiction Medicine)

    Education history

    Fellowship General Internal Medicine - VA Pittsburgh Healthcare System/㽶Ƶ of Pittsburgh Fellow
    Graduate Training Multidisciplinary - 㽶Ƶ of Pittsburgh Graduate School of Public Health M.P.H.
    Internship/Residency Internal Medicine - 㽶Ƶ of Pittsburgh Medical Center Intern/Resident
    Professional Medical Medicine - 㽶Ƶ of Pittsburgh School of Medicine M.D.
    Undergraduate Biological Sciences - Northwestern 㽶Ƶ B.A.

    Selected Publications

    Journal Article

    1. Hayes CJ, Raciborski RA, Martin BC, Gordon AJ, Hudson TJ, Brown CC, Pro G, Cucciare MA (2024). Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study. J Subst Use Addict Treat, 166, 209461. ()
    2. Seliski N, Madsen T, Eley S, Colosimo J, Engar T, Gordon A, Barnett C, Humiston G, Morsillo T, Stolebarger L, Smid MC, Cochran G (2024). Implementation of a rural emergency department-initiated buprenorphine program in the mountain west: a study protocol. Addict Sci Clin Pract, 19(1), 63. ()
    3. Incze MA, Huebler S, Szczotka K, Grant S, Kertesz SG, Gordon AJ (2024). Expert Panel Consensus on the Effectiveness and Implementation of Models to Support Posthospitalization Care Transitions for People With Substance Use Disorders. J Addict Med. ()
    4. Wyse JJ, Eckhardt A, Newell S, Gordon AJ, Morasco BJ, Carlson K, Korthuis PT, Ono SS, Lovejoy TI (2024). Integrating Buprenorphine for Opioid Use Disorder into Rural, Primary Care Settings. J Gen Intern Med, 39(12), 2142-2149. ()
    5. Winhusen TJ, Kropp F, Greenfield SF, Krans EE, Lewis D, Martin PR, Gordon AJ, Davies TH, Wachman EM, Douaihy A, Parker K, Xin X, Jalali A, Lofwall MR (2024). Trauma Prevalence and Its Association With Health-Related Quality of Life in Pregnant Persons with Opioid Use Disorder. J Addict Med. ()
    6. Kertesz SG, deRussy AJ, Hoge AE, Varley AL, Holmes SK, Riggs KR, Austin EL, Gordon AJ, Gabrielian SE, Pollio DE, Montgomery AE, Gelberg L, Steward JL, Jones AL, Richman JR (2024). Organizational and patient factors associated with positive primary care experiences for veterans with current or recent homelessness. Health Serv Res. ()
    7. Magel JS, Beneciuk JM, Siantz E, Fritz J, Garland EL, Hanley A, Shen J, Blosser P, Matev T, Gordon AJ (2024). PT-IN-MIND: study protocol for a multisite randomised feasibility trial investigating physical therapy with integrated mindfulness (PT-IN-MIND) for patients with chronic musculoskeletal pain and long-term opioid treatment who attend outpatient physical therapy. BMJ Open, 14(7), e082611. ()
    8. Hayes CJ, Martin BC, Hoggatt KJ, Cucciare MA, Hudson TJ, Gordon AJ (2024). Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder. Subst Use Addctn J, 29767342241263161. ()
    9. Khan MR, Acri M, Ban KF, Scheidell JD, Stevens ER, Manandhar-Sasaki P, Charles D, Chichetto NE, Crystal S, Gordon AJ, Marshall BDL, Edelman EJ, Justice AC, Braithwaite SR, Caniglia EC (2024). Associations Between Reductions in Depressive Symptoms and Reductions in Pain and Anxiety Symptoms and Substance Use: Emulation of a Randomized Trial. AJPM Focus, 3(5), 100258. ()
    10. Nakamoto CH, Huskamp HA, Donohue JM, Barnett ML, Gordon AJ, Mehrotra A (2024). Medicare Payment for Opioid Treatment Programs. JAMA Health Forum, 5(7), e241907. ()
    11. Wyse JJ, Mackey K, Kauzlarich KA, Morasco BJ, Carlson KF, Gordon AJ, Korthuis PT, Eckhardt A, Newell S, Ono SS, Lovejoy TI (2024). Improving access to buprenorphine for rural veterans in a learning health care system. Health Serv Res. ()
    12. Incze MA, Huebler S, Grant S, Gordon AJ (2024). Using the Delphi Process to Prioritize an Agenda for Care Transition Research for Patients With Substance Use Disorders. Subst Use Addctn J, 45(3), 523-528. ()
    13. Hayes CJ, Bin Noor N, Raciborski RA, Martin BC, Gordon AJ, Hoggatt KJ, Hudson T, Cucciare MA (2024). Development and validation of machine-learning algorithms predicting retention, overdoses, and all-cause mortality among US military veterans treated with buprenorphine for opioid use disorder. J Addict Dis, 1-18. ()
    14. Cooperman NA, Shen J, Gordon AJ, Garland EL (2024). Commentary With Study Protocol: Implementation and Effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) as an Adjunct to Methadone Treatment for Opioid Use Disorder (IMPOWR-MORE). Subst Use Addctn J, 29767342241261890. ()
    15. Richardson C, Daniels K, Confer A, Saxon AJ, Gordon AJ, Liberto J, Albanese AP, Renner J, Edens E, Kennedy AJ (2024). Internal Medicine Resident Addiction Training at the Veteran's Health Administration: A Qualitative Evaluation of Site Directors' Response to the 2022 ACGME Requirements. J Gen Intern Med, 39(8), 1393-1399. ()
    16. Schuler MS, Dick AW, Gordon AJ, Saloner B, Kerber R, Stein BD (2024). Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018. Drug Alcohol Depend, 259, 111290. ()
    17. Eckhardt A, Waller DE, Shull S, Lovejoy TI, Morasco BJ, Gordon AJ, Wyse JJ (2024). "They Ask Questions, But They Don't Want the Answers"-Perceptions of Clinical Communication Among Veterans Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder. Subst Use Addctn J, 29767342241251761. ()
    18. Magel J, Siantz E, Blosser P, Fritz JM, Gordon AJ (2024). The Development of an Opioid Misuse Training Program for Physical Therapists: A Learning Community Approach. J Phys Ther Educ. ()
    19. Freeman PR, Hammerslag LR, Ahrens KA, Sharbaugh M, Gordon AJ, Austin AE, Donohue JM, Allen LD, Barnes AJ, Talbert JC (2024). Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies. JAMA Health Forum, 5(5), e241077. ()
    20. Hawkins EJ, Malte CA, Hagedorn HJ, Gordon AJ, Williams EC, Trim RS, Blanchard BE, Lott A, Danner AN, Saxon AJ (2024). Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care. J Addict Med, 18(3), 240-247. ()
    21. Wyse JJ, Eckhardt A, Waller D, Gordon AJ, Shull S, Lovejoy TI, Mackey K, Morasco BJ (2024). Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder. J Addict Med, 18(3), 300-305. ()
    22. Hardy CJ, Cochran G, Howey W, Wright E, Wasan AD, Gordon AJ, Kraemer KL (2024). Impact of Provider-Facing Interventions to Reduce Opioid Use on Pain Related Outcomes in Primary Care: A Cluster Randomized Trial. Health Serv Res Manag Epidemiol, 11, 23333928241240957. ()
    23. Cox N, Hohmeier KC, Cernasev A, Field C, Elliott S, LaFleur G, Barland KM, Green M, Gardner JW, Gordon AJ, Cochran G (2024). Engaging community pharmacies in practice-based research: Lessons from opioid-focused research. Res Social Adm Pharm, 20(4), 457-462. ()
    24. Andraka-Christou B, Golan OK, Williams M, Buksbaum S, Gordon AJ, Stein BD (2024). A Systematic Review of State Office-Based Buprenorphine Treatment Laws Effective During 2022: Counseling, Dosage, and Visit Frequency Requirements. Subst Use Addctn J, 45(2), 278-291. ()
    25. McCollister KE, Gordon AJ, Acevedo A, Voshtina D, Li JM, Tse B, Murphy SM (2024). The 2023 Addiction Health Services Research Conference: Back in Person and Taking a Bite of the Big Apple. Subst Use Addctn J, 45(2), 163-167. ()
    26. Cochran G, Smid MC, Krans EE, Yu Z, Carlston K, White A, Abdulla W, Baylis J, Charron E, Okifugi A, Gordon AJ, Lundahl B, Silipigni J, Seliski N, Haaland B, Tarter R (2023). Patient navigation for pregnant individuals with opioid use disorder: Results of a randomized multi-site pilot trial. Addiction, 119(3), 544-556. ()
    27. Grant S, Smart R, Gordon AJ, Pacula RL, Stein BD (2023). Expert Views on State Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder: A Qualitative Analysis of an Online Modified Delphi Process. J Addict Med, 18(2), 129-137. ()
    28. Nock NL, Stoutenberg M, Cook DB, Whitworth JW, Janke EA, Gordon AJ (2024). Exercise as Medicine for People with a Substance Use Disorder: An ACSM Call to Action Statement. Curr Sports Med Rep, 23(2), 53-57. ()
    29. Goodman-Meza D, Goto M, Salimian A, Shoptaw S, Bui AAT, Gordon AJ, Goetz MB (2024). Impact of Potential Case Misclassification by Administrative Diagnostic Codes on Outcome Assessment of Observational Study for People Who Inject Drugs. Open Forum Infect Dis, 11(2), ofae030. ()
    30. Andraka-Christou B, Golan O, Totaram R, Ohama M, Saloner B, Gordon AJ, Stein BD (2023). Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019. Ann Med, 55(1), 514-520. ()
    31. Andraka-Christou B, McAvoy E, Gordon AJ, Ohama M, Brach M, Taylor EA, Vaiana M, Saloner B, Stein BD (2023). Urine drug testing in the context of opioid analgesic prescribing for chronic pain: a content analysis of U.S. state laws in 2022. Pain Med, 24(12), 1306-1317. ()
    32. Huang LC, Bleicher J, Torre M, Johnson JE, Presson A, Millar MM, Gordon AJ, Brooke BS, Kaphingst KA, Harris AHS (2023). Evaluating a health system-wide opioid disposal intervention distributing home-disposal bags. Health Serv Res, 58(6), 1256-1265. ()
    33. Bridges NC, Taber R, Foulds AL, Bear TM, Cloutier RM, McDonough BL, Gordon AJ, Cochran GT, Donohue JM, Adair D, DiDomenico E, Pringle JL, Gellad WF, Kelley D, Cole ES (2023). Medications for opioid use disorder in rural primary care practices: Patient and provider experiences. J Subst Use Addict Treat, 154, 209133. ()
    34. Bowman J, Lai M, Charles JE, Gordon AJ, Smid MC (2023). Kratom Use Among Pregnant and Lactating Individuals With Substance Use Disorder. J Addict Med, 17(6), 722-724. ()
    35. Golan OK, Sheng F, Dick AW, Sorbero M, Whitaker DJ, Andraka-Christou B, Pigott T, Gordon AJ, Stein BD (2023). Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018. Drug Alcohol Depend Rep, 9, 100193. ()
    36. Percy A, Kelley AT, Valentino N, Butz A, Baylis JD, Suo Y, Gordon AJ, Jones AL (2023). Care Practices of Mental Health Clinical Pharmacist Practitioners Within an Interdisciplinary Primary Care Model for Patients With Substance Use Disorders. Subst Abus, 44(4), 330-336. ()
    37. Miller WA, Gordon AJ, Clothier BA, Ackland PE, Bounthavong M, Garcia C, Kenny ME, Noorbaloochi S, Hagedorn HJ (2023). Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study. Implement Res Pract, 4, 26334895231199463. ()
    38. Ackland PE, Kenny ME, Clothier BA, Salameh HA, Boening N, Gordon AJ, Noorbaloochi S, Gustavson AM, Miller W, Hagedorn HJ (2023). What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA Facilities. J Gen Intern Med, 38(12), 2647-2654. ()
    39. Ackland PE, Kenny ME, Clothier BA, Salameh HA, Boening N, Gordon AJ, Noorbaloochi S, Gustavson AM, Miller W, Hagedorn HJ (2023). What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA Facilities. J Gen Intern Med, 38(12), 2647-2654. ()
    40. Hammerslag L, Talbert J, Donohue JM, Sharbaugh M, Ahrens K, Allen L, Austin AE, Gordon AJ, Jarlenski M, Kim JY, Mohamoud S, Tang L, Burns M, Writing committee for MODRN (2023). Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states. Drug Alcohol Depend, 250, 110875. ()
    41. Garcia CC, Bounthavong M, Gordon AJ, Gustavson AM, Kenny ME, Miller W, Esmaeili A, Ackland PE, Clothier BA, Bangerter A, Noorbaloochi S, Harris AHS, Hagedorn HJ (2023). Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorder. Implement Sci Commun, 4(1), 91. ()
    42. Saloner B, Whitley P, Dawson E, Passik S, Gordon AJ, Stein BD (2023). Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. Addiction, 118(8), 1549-1556. ()
    43. Gordon AJ, Saxon AJ, Kertesz S, Wyse JJ, Manhapra A, Lin LA, Chen W, Hansen J, Pinnell D, Huynh T, Baylis JD, Cunningham FE, Ghitza UE, Bart G, Yu H, Sauer BC (2023). Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug Alcohol Depend, 248, 109902. ()
    44. Schuler MS, Saloner B, Gordon AJ, Dick AW, Stein BD (2023). National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018. Subst Abus, 44(3), 154-163. ()
    45. Griffin BA, Cabreros I, Saloner B, Gordon AJ, Kerber R, Stein BD (2023). Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads. Subst Abus, 44(3), 136-145. ()
    46. Incze MA, Chen D, Galyean P, Kimball ER, Stolebarger L, Zickmund S, Gordon AJ (2023). Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study. J Addict Med, 17(4), 401-406. ()
    47. Lott AM, Danner AN, Malte CA, Williams EC, Gordon AJ, Halvorson MA, Saxon AJ, Hagedorn HJ, Sayre GG, Hawkins EJ (2023). Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation. J Addict Med, 17(4), e262-e268. ()
    48. Cernasev A, Hohmeier K, Field C, Gordon AJ, Elliott S, Carlston K, Broussard G, Cochran G (2023). Co-use of Opioid Medications and Alcohol Prevention Study (COAPS). Subst Abus, 44(3), 130-135. ()
    49. Austin AE, Tang L, Kim JY, Allen L, Barnes AJ, Chang CH, Clark S, Cole ES, Durrance CP, Donohue JM, Gordon AJ, Huskamp HA, McDuffie MJ, Mehrotra A, Mohamoud S, Talbert J, Ahrens KA, Applegate M, Hammerslag LR, Lanier P, Tossone K, Zivin K, Burns ME (2023). Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs. JAMA Health Forum, 4(6), e231422. ()
    50. Allen L, Medicaid Outcomes Distributed Research Network MODRN, Cole E, Sharbaugh M, Austin A, Burns M, Ho Chang CC, Clark S, Crane D, Cunningham P, Durrance C, Fry C, Gordon A, Hammerslag L, Kim JY, Kennedy S, Krishnan S, Mauk R, Talbert J, Tang L, Donohue JM (2023). Use of residential opioid use disorder treatment among Medicaid enrollees in nine states. J Subst Use Addict Treat, 149, 209034. ()
    51. Stein BD, Saloner BK, Golan OK, Andraka-Christou B, Andrews CM, Dick AW, Davis CS, Sheng F, Gordon AJ (2023). Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment. JAMA Health Forum, 4(5), e231102. ()
    52. Charron E, White A, Carlston K, Abdullah W, Baylis JD, Pierce S, Businelle MS, Gordon AJ, Krans EE, Smid MC, Cochran G (2023). Prospective acceptability of digital phenotyping among pregnant and parenting people with opioid use disorder: A multisite qualitative study. Front Psychiatry, 14, 1137071. ()
    53. Lott AM, Danner AN, Malte CA, Williams EC, Gordon AJ, Halvorson MA, Saxon AJ, Hagedorn HJ, Sayre GG, Hawkins EJ (2023). Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation. J Addict Med. ()
    54. Jones AL, Chu K, Rose DE, Gelberg L, Kertesz SG, Gordon AJ, Wells KB, Leung L (2023). Quality of Depression Care for Veterans Affairs Primary Care Patients with Experiences of Homelessness. J Gen Intern Med. ()
    55. Cloutier RM, Cole ES, McDonough BL, Lomauro DA, Miller JP, Talbert AL, Bear TM, Bridges NC, Foulds AL, Taber R, Gordon AJ, Cochran GT, Kmiec J, Donohue JM, Kelley D, DiDomenico E, Adair D, Pringle JL (2023). Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model. Implement Res Pract, 4, 26334895231152808. ()
    56. Charron E, Yu Z, Lundahl B, Silipigni J, Okifuji A, Gordon AJ, Baylis JD, White A, Carlston K, Abdullah W, Haaland B, Krans EE, Smid MC, Cochran G (2023). Cluster analysis to identify patient profiles and substance use patterns among pregnant persons with opioid use disorder. Addict Behav Rep, 17, 100484. ()
    57. Stein BD, Landis RK, Sheng F, Saloner B, Gordon AJ, Sorbero M, Dick AW (2022). Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention. J Gen Intern Med, 38(3), 733-737. ()
    58. Bershteyn A, Richard E, Zhou Q, Khan MR, Scheidell JD, Manandhar-Sasaki P, Ban K, Crystal S, Gordon AJ, Justice AC, Bryant KJ, Braithwaite RS (2022). Potential health benefits of integrated screening strategies for alcohol, tobacco, other substance use, depression, anxiety, and chronic pain among people living with HIV in the USA: a mathematical modelling study. Lancet HIV, 10(2), e118-e125. ()
    59. Incze MA, Chen D, Galyean P, Kimball ER, Stolebarger L, Zickmund S, Gordon AJ (2023). Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study. J Addict Med. ()
    60. Wyse JJ, Shull S, Lindner S, Morasco BJ, Gordon AJ, Carlson KF, Korthuis PT, Ono SS, Liberto JG, Lovejoy TI (2023). Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities. J Gen Intern Med, 1-6. ()
    61. Ahrens K, Sharbaugh M, Jarlenski MP, Tang L, Allen L, Austin AE, Barnes AJ, Burns ME, Clark S, Zivin K, Mack A, Liu G, Mohamoud S, McDuffie MJ, Hammerslag L, Gordon AJ, Donohue JM, Writing Committee for MODRN (2023). Prevalence of testing for HIV, HBV, and HCV among Medicaid enrollees treated with medications for opioid use disorder in 11 states, 2016-2019. Clin Infect Dis. ()
    62. Jones AL, Kelley AT, Suo Y, Baylis JD, Codell NK, West NA, Gordon AJ (2022). Trends in Health Service Utilization After Enrollment in an Interdisciplinary Primary Care Clinic for Veterans with Addiction, Social Determinants of Health, or Other Vulnerabilities. J Gen Intern Med, 38(1), 12-20. ()
    63. Hickey TR, Henry JT, Edens EL, Gordon AJ, Acampora G (2022). Perioperative Management of Extended-release Buprenorphine. J Addict Med, 17(1), e67-e71. ()
    64. Scheidell JD, Townsend T, Ban KF, Caniglia EC, Charles D, Edelman EJ, Marshall BDL, Gordon AJ, Justice AC, Braithwaite RS, Khan MR (2022). Cessation of self-reported opioid use and impacts on co-occurring health conditions. Drug Alcohol Depend, 242, 109712. ()
    65. Magel J, Hartman P, Fritz JM, Koch NN, Dostal H, Vollmer N, Ferguson NL, Tapken J, Cohee K, Cochran G, Gordon AJ (2023). Patients' Perceptions of Physical Therapists Addressing Opioid Misuse. Subst Abus, 44(1), 32-40. ()
    66. Wyse JJ, Lovejoy TI, Gordon AJ, Mackey K, Herreid-ONeill A, Morasco BJ (2023). "I'm Clean and Sober, But Not Necessarily Free": Perceptions of Buprenorphine Among Patients in Long-Term Treatment. Subst Abus, 44(1), 41-50. ()
    67. deRussy AJ, Jones AL, Austin EL, Gordon AJ, Gelberg L, Gabrielian SE, Riggs KR, Blosnich JR, Montgomery AE, Holmes SK, Varley AL, Hoge AE, Kertesz SG (2021). Insights for Conducting Large-Scale Surveys with Veterans Who Have Experienced Homelessness. J Soc Distress Homeless, 32(1), 123-134. ()
    68. Kelley AT, Wilcox J, Baylis JD, Crossnohere NL, Magel J, Jones AL, Gordon AJ, Bridges JFP (2022). Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives. J Gen Intern Med. ()
    69. Landis RK, Levin JS, Saloner B, Gordon AJ, Dick AW, Sherry TB, Leslie DL, Sorbero M, Stein BD (2023). Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. Subst Abus, 43(1), 1057-1071. ()
    70. Burns M, Tang L, Chang CH, Kim JY, Ahrens K, Allen L, Cunningham P, Gordon AJ, Jarlenski MP, Lanier P, Mauk R, McDuffie MJ, Mohamoud S, Talbert J, Zivin K, Donohue J (2022). Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study. Addiction, 117(12), 3079-3088. ()
    71. Landis RK, Opper I, Saloner B, Gordon AJ, Leslie DL, Sorbero M, Stein BD (2022). Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies. Drug Alcohol Depend, 241, 109669. ()
    72. Medicaid Outcomes Distributed Research Network MODRN, Cole ES, Allen L, Austin A, Barnes A, Chang CH, Clark S, Crane D, Cunningham P, Fry CE, Gordon AJ, Hammerslag L, Idala D, Kennedy S, Kim JY, Krishnan S, Lanier P, Mahakalanda S, Mauk R, McDuffie MJ, Mohamoud S, Talbert J, Tang L, Zivin K, Donohue JM (2022). Outpatient follow-up and use of medications for opioid use disorder after residential treatment among Medicaid enrollees in 10 states. Drug Alcohol Depend, 241, 109670. ()
    73. Haque LY, Fiellin DA, Tate JP, Esserman D, Bhattacharya D, Butt AA, Crystal S, Edelman EJ, Gordon AJ, Lim JK, Tetrault JM, Williams EC, Bryant K, Cartwright EJ, Rentsch CT, Justice AC, Lo Re V 3rd, McGinnis KA (2022). Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Netw Open, 5(12), e2246604. ()
    74. Hagedorn HJ, Gustavson AM, Ackland PE, Bangerter A, Bounthavong M, Clothier B, Harris AHS, Kenny ME, Noorbaloochi S, Salameh HA, Gordon AJ (2022). Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities. J Gen Intern Med, 37(14), 3594-3602. ()
    75. Varley AL, Hoge A, Riggs KR, deRussy A, Jones AL, Austin EL, Gabrielian S, Gelberg L, Gordon AJ, Blosnich JR, Montgomery AE, Kertesz SG (2022). What do Veterans with homeless experience want us to know that we are not asking? A qualitative content analysis of comments from a national survey of healthcare experience. Health Soc Care Community, 30(6), e5027-e5037. ()
    76. Riggs KR, DeRussy AJ, Leisch L, Shover CL, Bohnert ASB, Hoge AE, Montgomery AE, Varley AL, Jones AL, Gordon AJ, Kertesz SG (2022). Sensitivity of health records for self-reported nonfatal drug and alcohol overdose. Am J Addict, 31(6), 517-522. ()
    77. Goodman-Meza D, Tang A, Aryanfar B, Vazquez S, Gordon AJ, Goto M, Goetz MB, Shoptaw S, Bui AAT (2022). Natural Language Processing and Machine Learning to Identify People Who Inject Drugs in Electronic Health Records. Open Forum Infect Dis, 9(9), ofac471. ()
    78. Smart R, Grant S, Gordon AJ, Pacula RL, Stein BD (2022). Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder. JAMA Health Forum, 3(9), e223285. ()
    79. Zivin K, Allen L, Barnes AJ, Junker S, Kim JY, Tang L, Kennedy S, Ahrens KA, Burns M, Clark S, Cole E, Crane D, Idala D, Lanier P, Mohamoud S, Jarlenski M, McDuffie MJ, Talbert J, Gordon AJ, Donohue JM (2022). Design, Implementation, and Evolution of the Medicaid Outcomes Distributed Research Network (MODRN). Med Care, 60(9), 680-690. ()
    80. McCarthy SA, Chinman M, Rogal SS, Klima G, Hausmann LRM, Mor MK, Shah M, Hale JA, Zhang H, Gordon AJ, Gellad WF (2022). Tracking the randomized rollout of a Veterans Affairs opioid risk management tool: A multi-method implementation evaluation using the Consolidated Framework for Implementation Research (CFIR). Implement Res Pract, 3, 26334895221114665. ()
    81. Magel J, Bishop MD, Lonnemann E, Cochran G, Fritz JM, West N, Gordon AJ (2021). The association between advanced orthopedic certification and confidence and engagement in prescription opioid medication misuse management practices: a cross-sectional study. J Man Manip Ther, 30(4), 228-238. ()
    82. Guo J, Gellad WF, Yang Q, Weiss JC, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Kuza CC, Wilson DL, Lo-Ciganic WH (2022). Changes in predicted opioid overdose risk over time in a state Medicaid program: a group-based trajectory modeling analysis. Addiction, 117(8), 2254-2263. ()
    83. Kraemer KL, Althouse AD, Salay M, Gordon AJ, Wright E, Anisman D, Cochran G, Fischer G, Gellad WF, Hamm M, Kern M, Wasan AD (2022). Effect of Different Interventions to Help Primary Care Clinicians Avoid Unsafe Opioid Prescribing in Opioid-Naive Patients With Acute Noncancer Pain: A Cluster Randomized Clinical Trial. JAMA Health Forum, 3(7), e222263. ()
    84. Andraka-Christou B, Saloner B, Gordon AJ, Totaram R, Randall-Kosich O, Golan M, Stein BD (2022). Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C. Am J Drug Alcohol Abuse, 48(4), 492-503. ()
    85. Andraka-Christou B, Gordon AJ, Spetz J, Totaram R, Golan M, Randall-Kosich O, Harrison J, Calder S, Kertesz SG, Stein BD (2022). Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing. J Subst Abuse Treat, 138, 108715. ()
    86. Lo-Ciganic WH, Donohue JM, Yang Q, Huang JL, Chang CY, Weiss JC, Guo J, Zhang HH, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Wilson DL, Kuza CC, Gellad WF (2021). Developing and validating a machine-learning algorithm to predict opioid overdose in Medicaid beneficiaries in two US states: a prognostic modelling study. Lancet Digit Health, 4(6), e455-e465. ()
    87. Incze MA, Kelley AT, Gordon AJ (2022). Champions Among Us: Leading Primary Care to the Forefront of Opioid Use Disorder Treatment. J Gen Intern Med, 37(7), 1771-1773. ()
    88. Stein BD, Saloner B, Kerber R, Sorbero M, Gordon AJ (2022). Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020. Ann Emerg Med, 79(5), 441-450. ()
    89. Perry C, Liberto J, Milliken C, Burden J, Hagedorn H, Atkinson T, McKay JR, Mooney L, Sall J, Sasson C, Saxon A, Spevak C, Gordon AJ, VADoD Guideline Development Group (2022). The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med, 175(5), 720-731. ()
    90. Cochran G, Shen J, Cox N, Field C, Carlston K, Sengpraseut B, White A, Okifuji A, Jackman C, Haaland B, Ragsdale R, Gordon AJ, Tarter R (2022). Addressing opioid medication misuse at point of service in community pharmacy: A study protocol for an interdisciplinary behavioral health trial. Contemp Clin Trials, 116, 106759. ()
    91. Radmall AO, Calder S, Codell N, Kelley AT, Hawkins E, Jones AL, Hagedorn HJ, Reynolds MA, Gordon AJ (2022). Roles and Perceptions of Nurses During Implementation of a Medication Treatment for Opioid Use Disorder National Initiative. J Addict Nurs, 33(2), 70-79. ()
    92. Andraka-Christou B, Randall-Kosich O, Golan M, Totaram R, Saloner B, Gordon AJ, Stein BD (2022). A national survey of state laws regarding medications for opioid use disorder in problem-solving courts. Health Justice, 10(1), 14. ()
    93. Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL (2021). Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS Behav, 26(3), 975-985. ()
    94. McGinnis KA, Tate JP, Bryant KJ, Justice AC, OConnor PG, Rodriguez-Barradas MC, Crystal S, Cutter CJ, Hansen NB, Maisto SA, Marconi VC, Williams EC, Cook RL, Gordon AJ, Gordon KS, Eyawo O, Edelman EJ, Fiellin DA (2021). Change in Alcohol Use Based on Self-Report and a Quantitative Biomarker, Phosphatidylethanol, in People With HIV. AIDS Behav, 26(3), 786-794. ()
    95. Gordon AJ, Kenny M, Dungan M, Gustavson AM, Kelley AT, Jones AL, Hawkins E, Frank JW, Danner A, Liberto J, Hagedorn H (2022). Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings. Am J Addict, 31(2), 152-158. ()
    96. Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R (2022). Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addict Sci Clin Pract, 17(1), 6. ()
    97. White A, Lundahl B, Bryan MA, Okifuji A, Smid M, Gordon AJ, Carlston K, Silipigni J, Abdullah W, Krans EE, Kenney A, Cochran G (2021). Pregnancy and the Opioid Crisis: Heightened Effects of COVID-19. J Addict Med, 16(1), e2-e4. ()
    98. Magel JJ, Cochran G, West N, Fritz JM, Bishop MD, Gordon AJ (2021). Physical therapists' attitudes are associated with their confidence in and the frequency with which they engage in prescription opioid medication misuse management practices with their patients. A cross-sectional study. Subst Abus, 43(1), 433-441. ()
    99. Williams AR, Johnson KA, Thomas CP, Reif S, Socas ME, Henry BF, Neighbors C, Gordon AJ, Horgan C, Nosyk B, Drexler K, Krawczyk N, Gonsalves GS, Hadland SE, Stein BD, Fishman M, Kelley AT, Pincus HA, Olfson M (2022). Opioid use disorder Cascade of care framework design: A roadmap. Subst Abus, 43(1), 1207-1214. ()
    100. Hawkins EJ, Malte CA, Gordon AJ, Williams EC, Hagedorn HJ, Drexler K, Blanchard BE, Burden JL, Knoeppel J, Danner AN, Lott A, Liberto JG, Saxon AJ (2021). Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System. JAMA Netw Open, 4(12), e2137238. ()
    101. Wyse JJ, Morasco BJ, Dougherty J, Edwards B, Kansagara D, Gordon AJ, Korthuis PT, Tuepker A, Lindner S, Mackey K, Williams B, Herreid-ONeill A, Paynter R, Lovejoy TI (2021). Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence. Drug Alcohol Depend, 228, 108923. ()
    102. Cabreros I, Griffin BA, Saloner B, Gordon AJ, Kerber R, Stein BD (2021). Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories. Drug Alcohol Depend, 228, 109089. ()
    103. Spelman JF, Edens EL, Maya S, Moore BA, Boggs A, MacLean RR, Ackland P, Becker WC, Lynch D, Garcia-Vassallo M, Burgo AL, Rosen MI, Gordon AJ (2021). A Facility-Wide Plan to Increase Access to Medication for Opioid Use Disorder in Primary Care and General Mental Health Settings. Fed Pract, 38(10), 460-464. ()
    104. Hawkins EJ, Danner AN, Malte CA, Blanchard BE, Williams EC, Hagedorn HJ, Gordon AJ, Drexler K, Burden JL, Knoeppel J, Lott A, Sayre GG, Midboe AM, Saxon AJ (2021). Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities. Addict Sci Clin Pract, 16(1), 55. ()
    105. Kertesz SG, DeRussy AJ, Riggs KR, Hoge AE, Varley AL, Montgomery AE, Austin EL, Blosnich JR, Jones AL, Gabrielian SE, Gelberg L, Gordon AJ, Richman JS (2021). Characteristics Associated With Unsheltered Status Among Veterans. Am J Prev Med, 61(3), 357-368. ()
    106. Gustavson AM, Kenny ME, Wisdom JP, Salameh HA, Ackland PE, Gordon AJ, Hagedorn HJ (2021). Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention. Addict Sci Clin Pract, 16(1), 51. ()
    107. Medicaid Outcomes Distributed Research Network MODRN, Donohue JM, Jarlenski MP, Kim JY, Tang L, Ahrens K, Allen L, Austin A, Barnes AJ, Burns M, Chang CH, Clark S, Cole E, Crane D, Cunningham P, Idala D, Junker S, Lanier P, Mauk R, McDuffie MJ, Mohamoud S, Pauly N, Sheets L, Talbert J, Zivin K, Gordon AJ, Kennedy S (2021). Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. JAMA, 326(2), 154-164. ()
    108. Kertesz SG, deRussy AJ, Kim YI, Hoge AE, Austin EL, Gordon AJ, Gelberg L, Gabrielian SE, Riggs KR, Blosnich JR, Montgomery AE, Holmes SK, Varley AL, Pollio DE, Gundlapalli AV, Jones AL (2021). Comparison of Patient Experience Between Primary Care Settings Tailored for Homeless Clientele and Mainstream Care Settings. Med Care, 59(6), 495-503. ()
    109. Jones AL, Gordon AJ, Gabrielian SE, Montgomery AE, Blosnich JR, Varley AL, deRussy AJ, Austin EL, Hoge AE, Kim YI, Gelberg L, Kertesz SG (2022). Perceptions of Care Coordination Among Homeless Veterans Receiving Medical Care in the Veterans Health Administration and Community Care Settings: Results From a National Survey. Med Care, 59(6), 504-512. ()
    110. Stein BD, Saloner B, Schuler MS, Gurvey J, Sorbero M, Gordon AJ (2021). Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US. JAMA, 325(21), 2206-2208. ()
    111. Kennedy AJ, McGinnis KA, Merlin JS, Edelman EJ, Gordon AJ, Korthuis PT, Skanderson M, Williams EC, Wyse J, Oldfield B, Bryant K, Justice A, Fiellin DA, Kraemer KL (2021). Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. J Subst Abuse Treat, 132, 108509. ()
    112. Andraka-Christou B, Gordon AJ, Bouskill K, Smart R, Randall-Kosich O, Golan M, Totaram R, Stein BD (2021). Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes from a Review of State Laws. J Addict Med. ()
    113. Cochran G, Cole ES, Sharbaugh M, Nagy D, Gordon AJ, Gellad WF, Pringle J, Bear T, Warwick J, Drake C, Chang CH, DiDomenico E, Kelley D, Donohue J (2021). Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder. J Addict Med. ()
    114. Magel JS, Gordon AJ, Fritz JM, Kim J (2022). The Influence of an Opioid Use Disorder on Initiating Physical Therapy for Low Back Pain: A Retrospective Cohort. J Addict Med, 15(3), 226-232. ()
    115. Andraka-Christou B, Bouskill K, Haffajee RL, Randall-Kosich O, Golan M, Totaram R, Gordon AJ, Stein BD (2021). Common themes in early state policy responses to substance use disorder treatment during COVID-19. Am J Drug Alcohol Abuse, 1-11. ()
    116. Guo J, Lo-Ciganic WH, Yang Q, Huang JL, Weiss JC, Cochran G, Malone DC, Kuza CC, Gordon AJ, Donohue JM, Gellad WF (2021). Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. J Gen Intern Med, 36(4), 908-915. ()
    117. Cole ES, Drake C, DiDomenico E, Sharbaugh M, Kim JY, Nagy D, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CH, Kmiec J, Kelley D, Donohue JM (2021). Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population. Drug Alcohol Depend, 221, 108633. ()
    118. Codell N, Kelley AT, Jones AL, Dungan MT, Valentino N, Holtey AI, Knight TJ, Butz A, Gallop C, Erickson S, Patton J, Hyte-Richins LJ, Rollins BZ, Gordon AJ (2020). Aims, development, and early results of an interdisciplinary primary care initiative to address patient vulnerabilities. Am J Drug Alcohol Abuse, 47(2), 160-169. ()
    119. Gustavson AM, Wisdom JP, Kenny ME, Salameh HA, Ackland PE, Clothier B, Noorbaloochi S, Gordon AJ, Hagedorn HJ (2021). Early impacts of a multi-faceted implementation strategy to increase use of medication treatments for opioid use disorder in the Veterans Health Administration. Implement Sci Commun, 2(1), 20. ()
    120. Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM, Ilgen MA (2020). Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction, 116(1), 96-104. ()
    121. Williams EC, McGinnis KA, Rubinsky AD, Matson TE, Bobb JF, Lapham GT, Edelman EJ, Satre DD, Catz SL, Richards JE, Bryant KJ, Marshall BDL, Kraemer KL, Crystal S, Gordon AJ, Skanderson M, Fiellin DA, Justice AC, Bradley KA (2022). Alcohol Use and Antiretroviral Adherence Among Patients Living with HIV: Is Change in Alcohol Use Associated with Change in Adherence? AIDS Behav, 25(1), 203-214. ()
    122. Hagle HN, Martin M, Winograd R, Merlin J, Finnell DS, Bratberg JP, Gordon AJ, Johnson C, Levy S, MacLane-Baeder D, Northup R, Weinstein Z, Lum PJ (2021). Dismantling racism against Black, Indigenous, and people of color across the substance use continuum: A position statement of the association for multidisciplinary education and research in substance use and addiction. Subst Abus, 42(1), 5-12. ()
    123. Gabrielian S, Jones AL, Hoge AE, deRussy AJ, Kim YI, Montgomery AE, Blosnich JR, Gordon AJ, Gelberg L, Austin EL, Pollio D, Holmes SK, Varley AL, Kertesz SG (2021). Enhancing Primary Care Experiences for Homeless Patients with Serious Mental Illness: Results from a National Survey. J Prim Care Community Health, 12, 2150132721993654. ()
    124. Saloner B, Andraka Christou B, Gordon AJ, Stein BD (2021). It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver. Subst Abus, 42(2), 153-157. ()
    125. Magel J, Kietrys D, Kruger ES, Fritz JM, Gordon AJ (2021). Physical therapists should play a greater role in managing patients with opioid use and opioid misuse. Subst Abus, 42(3), 255-260. ()
    126. Joudrey PJ, Bart G, Brooner RK, Brown L, Dickson-Gomez J, Gordon A, Kawasaki SS, Liebschutz JM, Nunes E, McCarty D, Schwartz RP, Szapocnik J, Trivedi M, Tsui JI, Williams A, Wu LT, Fiellin DA (2021). Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report. Subst Abus, 42(3), 245-254. ()
    127. Jones AL, Gelberg L, deRussy AJ, Varley AL, Riggs KR, Gordon AJ, Kertesz SG (2020). Low Uptake of Secure Messaging Among Veterans With Experiences of Homelessness and Substance Use Disorders. J Addict Med, 15(6), 508-511. ()
    128. Kelley AT, Dungan MT, Gordon AJ (2020). Barriers and Facilitators to Buprenorphine Prescribing for Opioid Use Disorder in the Veterans Health Administration During COVID-19. J Addict Med, 15(5), 439-440. ()
    129. Gordon AJ, Choi JH, Ginsburg H, Kuenzler K, Fisher J, Tomita S (2020). Oral Antibiotics and Abscess Formation After Appendectomy for Perforated Appendicitis in Children. J Surg Res, 256, 56-60. ()
    130. McGinnis KA, Skanderson M, Edelman EJ, Gordon AJ, Korthuis PT, Oldfield B, Williams EC, Wyse J, Bryant K, Fiellin DA, Justice AC, Kraemer KL (2020). Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. Drug Alcohol Depend, 217, 108272. ()
    131. Caniglia EC, Stevens ER, Khan M, Young KE, Ban K, Marshall BDL, Chichetto NE, Gaither JR, Crystal S, Edelman EJ, Fiellin DA, Gordon AJ, Bryant KJ, Tate J, Justice AC, Braithwaite RS (2020). Does Reducing Drinking in Patients with Unhealthy Alcohol Use Improve Pain Interference, Use of Other Substances, and Psychiatric Symptoms? Alcohol Clin Exp Res, 44(11), 2257-2265. ()
    132. Bryan MA, Smid MC, Cheng M, Fortenberry KT, Kenney A, Muniyappa B, Pendergrass D, Gordon AJ, Cochran G (2020). Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol. Addict Sci Clin Pract, 15(1), 33. ()
    133. Nevid JS, Gordon AJ, Haggerty G (2019). Clinical Utility of the Personality Assessment Inventory in Predicting Symptom Change and Clinical Outcome in an Inpatient Chemical Dependency Rehabilitation Unit. J Pers Assess, 102(5), 587-593. ()
    134. Lobo CP, Cochran G, Chang CH, Gellad WF, Gordon AJ, Jalal H, Lo-Ciganic WH, Karp JF, Kelley D, Donohue JM (2019). Associations Between the Specialty of Opioid Prescribers and Opioid Addiction, Misuse, and Overdose Outcomes. Pain Med, 21(9), 1871-1890. ()
    135. Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Kwoh CK, Donohue JM, Gordon AJ, Cochran G, Malone DC, Kuza CC, Gellad WF (2020). Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study. PLoS One, 15(7), e0235981. ()
    136. Rogal SS, Chinman M, Gellad WF, Mor MK, Zhang H, McCarthy SA, Mauro GT, Hale JA, Lewis ET, Oliva EM, Trafton JA, Yakovchenko V, Gordon AJ, Hausmann LRM (2020). Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative. Implement Sci, 15(1), 48. ()
    137. Blosnich JR, Montgomery AE, Dichter ME, Gordon AJ, Kavalieratos D, Taylor L, Ketterer B, Bossarte RM (2019). Social Determinants and Military Veterans' Suicide Ideation and Attempt: a Cross-sectional Analysis of Electronic Health Record Data. J Gen Intern Med, 35(6), 1759-1767. ()
    138. Jones AL, Kertesz SG, Hausmann LRM, Mor MK, Suo Y, Pettey WBP, Schaefer JH Jr, Gundlapalli AV, Gordon AJ (2020). Primary care experiences of veterans with opioid use disorder in the Veterans Health Administration. J Subst Abuse Treat, 113, 107996. ()
    139. Kertesz SG, Manhapra A, Gordon AJ (2020). Nonconsensual Dose Reduction Mandates are Not Justified Clinically or Ethically: An Analysis. J Law Med Ethics, 48(2), 259-267. ()
    140. Varley AL, Montgomery AE, Steward J, Stringfellow E, Austin EL, Gordon AJ, Pollio D, deRussy A, Hoge A, Gelberg L, Riggs K, Kim TW, Rubens SL, Kertesz SG (2020). Exploring Quality of Primary Care for Patients Who Experience Homelessness and the Clinicians Who Serve Them: What Are Their Aspirations? Qual Health Res, 30(6), 865-879. ()
    141. Oliva EM, Bowe T, Manhapra A, Kertesz S, Hah JM, Henderson P, Robinson A, Paik M, Sandbrink F, Gordon AJ, Trafton JA (2020). Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ, 368, m283. ()
    142. Riggs KR, Hoge AE, DeRussy AJ, Montgomery AE, Holmes SK, Austin EL, Pollio DE, Kim YI, Varley AL, Gelberg L, Gabrielian SE, Blosnich JR, Merlin J, Gundlapalli AV, Jones AL, Gordon AJ, Kertesz SG (2020). Prevalence of and Risk Factors Associated With Nonfatal Overdose Among Veterans Who Have Experienced Homelessness. JAMA Netw Open, 3(3), e201190. ()
    143. Oldfield BJ, McGinnis KA, Edelman EJ, Williams EC, Gordon AJ, Akgn K, Crystal S, Fiellin LE, Gaither JR, Goulet JL, Korthuis PT, Marshall BDL, Justice AC, Bryant K, Fiellin DA, Kraemer KL (2019). Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. J Subst Abuse Treat, 109, 14-22. ()
    144. Kagabo R, Gordon AJ, Okuyemi K (2020). Smoking cessation in inpatient psychiatry treatment facilities: A review. Addict Behav Rep, 11, 100255. ()
    145. Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, Dungan MT, Hagedorn H (2020). Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus, 41(3), 275-282. ()
    146. Stevens ER, Mazumdar M, Caniglia EC, Khan MR, Young KE, Edelman EJ, Gordon AJ, Fiellin DA, Maisto SA, Chichetto NE, Crystal S, Gaither JR, Justice AC, Braithwaite RS (2020). Insights Provided by Depression Screening Regarding Pain, Anxiety, and Substance use in a Veteran Population. J Prim Care Community Health, 11, 2150132720949123. ()
    147. Gustavson AM, Gordon AJ, Kenny ME, McHenry H, Gronek J, Ackland PE, Hagedorn HJ (2020). Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder. Subst Abus, 41(4), 413-418. ()
    148. Rentsch CT, Edelman EJ, Justice AC, Marshall BDL, Xu K, Smith AH, Crystal S, Gaither JR, Gordon AJ, Smith RV, Kember RL, Polimanti R, Gelernter J, Fiellin DA, Tate JP, Kranzler HR, Becker WC, VACS Project Team (2019). Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. AIDS Behav, 23(12), 3340-3349. ()
    149. Cochran G, Chen Q, Field C, Seybert AL, Hruschak V, Jaber A, Gordon AJ, Tarter R (2019). A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial. Drug Alcohol Depend, 205, 107570. ()
    150. Cochran G, Smid MC, Krans EE, Bryan MA, Gordon AJ, Lundahl B, Silipigni J, Haaland B, Tarter R (2019). A pilot multisite study of patient navigation for pregnant women with opioid use disorder. Contemp Clin Trials, 87, 105888. ()
    151. Liu F, Pradhan R, Druhl E, Freund E, Liu W, Sauer BC, Cunningham F, Gordon AJ, Peters CB, Yu H (2018). Learning to detect and understand drug discontinuation events from clinical narratives. J Am Med Inform Assoc, 26(10), 943-951. ()
    152. Carter SP, Montgomery AE, Henderson ER, Ketterer B, Dichter M, Gordon AJ, Shipherd JC, Kauth MR, Blosnich JR (2019). Housing Instability Characteristics Among Transgender Veterans Cared for in the Veterans Health Administration, 2013-2016. Am J Public Health, 109(10), 1413-1418. ()
    153. Moyo P, Gellad WF, Sabik LM, Cochran GT, Cole ES, Gordon AJ, Kelley DK, Donohue JM (2018). Opioid Prescribing Safety Measures in Medicaid Enrollees With and Without Cancer. Am J Prev Med, 57(4), 540-544. ()
    154. Banerjee G, Edelman EJ, Barry DT, Crystal S, Gordon KS, Gordon AJ, Gaither JR, Green TC, Kerns RD, Manhapra A, Moore BA, Fiellin DA, Marshall BDL (2019). High-dose prescribed opioids are associated with increased risk of heroin use among United States military veterans. Pain, 160(9), 2126-2135. ()
    155. Kraemer KL, McGinnis KA, Fiellin DA, Skanderson M, Gordon AJ, Robbins J, Zickmund S, Bryant K, Korthuis PT (2019). Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans. J Subst Abuse Treat, 103, 23-32. ()
    156. Cochran G, Cole ES, Warwick J, Donohue JM, Gordon AJ, Gellad WF, Bear T, Kelley D, DiDomenico E, Pringle J (2019). Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers. Addict Sci Clin Pract, 14(1), 25. ()
    157. Cole ES, DiDomenico E, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CH, Kim JY, Kmiec J, Kelley D, Donohue JM (2019). The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder. J Gen Intern Med, 34(6), 936-943. ()
    158. Smid MC, Stone NM, Baksh L, Debbink MP, Einerson BD, Varner MW, Gordon AJ, Clark EAS (2019). Pregnancy-Associated Death in Utah: Contribution of Drug-Induced Deaths. Obstet Gynecol, 133(6), 1131-1140. ()
    159. Wyse JJ, Robbins JL, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Gaither JR, Gordon K, Skanderson M, Barry DT, Crystal S, Justice A, Kraemer KL (2019). Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug Alcohol Depend, 198, 70-75. ()
    160. Jones AL, Hausmann LRM, Kertesz SG, Suo Y, Cashy JP, Mor MK, Pettey WBP, Schaefer JH Jr, Gordon AJ, Gundlapalli AV (2019). Providing Positive Primary Care Experiences for Homeless Veterans Through Tailored Medical Homes: The Veterans Health Administration's Homeless Patient Aligned Care Teams. Med Care, 57(4), 270-278. ()
    161. Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad WF (2019). Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA Netw Open, 2(3), e190968. ()
    162. Edelman EJ, Gordon KS, Crothers K, Akgn K, Bryant KJ, Becker WC, Gaither JR, Gibert CL, Gordon AJ, Marshall BDL, Rodriguez-Barradas MC, Samet JH, Justice AC, Tate JP, Fiellin DA (2019). Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA Intern Med, 179(3), 297-304. ()
    163. Smid MC, Metz TD, Gordon AJ (2019). Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. Clin Obstet Gynecol, 62(1), 168-184. ()
    164. Darnall BD, Juurlink D, Kerns RD, Mackey S, Van Dorsten B, Humphreys K, Gonzalez-Sotomayor JA, Furlan A, Gordon AJ, Gordon DB, Hoffman DE, Katz J, Kertesz SG, Satel S, Lawhern RA, Nicholson KM, Polomano RC, Williamson OD, McAnally H, Kao MC, Schug S, Twillman R, Lewis TA, Stieg RL, Lorig K, Mallick-Searle T, West RW, Gray S, Ariens SR, Sharpe Potter J, Cowan P, Kollas CD, Laird D, Ingle B, Julian Grove J, Wilson M, Lockman K, Hodson F, Palackdharry CS, Fillingim RB, Fudin J, Barnhouse J, Manhapra A, Henson SR, Singer B, Ljosenvoor M, Griffith M, Doctor JN, Hardin K, London C, Mankowski J, Anderson A, Ellsworth L, Davis Budzinski L, Brandt B, Hartley G, Nickels Heck D, Zobrosky MJ, Cheek C, Wilson M, Laux CE, Datz G, Dunaway J, Schonfeld E, Cady M, LeDantec-Boswell T, Craigie M, Sturgeon J, Flood P, Giummarra M, Whelan J, Thorn BE, Martin RL, Schatman ME, Gregory MD, Kirz J, Robinson P, Marx JG, Stewart JR, Keck PS, Hadland SE, Murphy JL, Lumley MA, Brown KS, Leong MS, Fillman M, Broatch JW, Perez A, Watford K, Kruska K, Sophia You D, Ogbeide S, Kukucka A, Lawson S, Ray JB, Wade Martin T, Lakehomer JB, Burke A, Cohen RI, Grinspoon P, Rubenstein MS, Sutherland S, Walters K, Lovejoy T (2019). International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on Forced Opioid Tapering. Pain Med, 20(3), 429-433. ()
    165. Nevid JS, Gordon AJ, Barris A, Sperber JE, Haggerty G (2019). Personality profiles of patients with alcohol use disorder and opioid use disorder in an inpatient treatment setting. J Subst Abuse Treat, 97, 91-96. ()
    166. McCall JD, Rodriguez KL, Barnisin-Lange D, Gordon AJ (2019). A Qualitative Examination of the Experiences of Veterans Treatment Court Graduates in Allegheny County, Pennsylvania. Int J Offender Ther Comp Criminol, 63(3), 339-356. ()
    167. Chinman M, Gellad WF, McCarthy S, Gordon AJ, Rogal S, Mor MK, Hausmann LRM (2019). Protocol for evaluating the nationwide implementation of the VA Stratification Tool for Opioid Risk Management (STORM). Implement Sci, 14(1), 5. ()
    168. Blosnich JR, Rodriguez KL, Hruska KL, Kavalieratos D, Gordon AJ, Matza A, Mejia SM, Shipherd JC, Kauth MR (2019). Utilization of the Veterans Affairs' Transgender E-consultation Program by Health Care Providers: Mixed-Methods Study. JMIR Med Inform, 7(1), e11695. ()
    169. Kertesz SG, Gordon AJ (2019). A crisis of opioids and the limits of prescription control: United States. Addiction, 114(1), 169-180. ()
    170. Williams EC, McGinnis KA, Edelman EJ, Matson TE, Gordon AJ, Marshall BDL, Bryant KJ, Rubinsky AD, Lapham GT, Satre DD, Richards JE, Catz SL, Fiellin DA, Justice AC, Bradley KA (2019). Level of Alcohol Use Associated with HIV Care Continuum Targets in a National U.S. Sample of Persons Living with HIV Receiving Healthcare. AIDS Behav, 23(1), 140-151. ()
    171. Hagedorn H, Kenny M, Gordon AJ, Ackland PE, Noorbaloochi S, Yu W, Harris AHS (2018). Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addict Sci Clin Pract, 13(1), 25. ()
    172. Smid MC, Charles JE, Gordon AJ, Wright TE (2018). Use of Kratom, an Opioid-like Traditional Herb, in Pregnancy. Obstet Gynecol, 132(4), 926-928. ()
    173. Barry DT, Marshall BDL, Becker WC, Gordon AJ, Crystal S, Kerns RD, Gaither JR, Gordon KS, Justice AC, Fiellin DA, Edelman EJ (2018). Duration of opioid prescriptions predicts incident nonmedical use of prescription opioids among U.S. veterans receiving medical care. Drug Alcohol Depend, 191, 348-354. ()
    174. Cochran G, Lo-Ciganic WH, Gellad WF, Gordon AJ, Cole E, Lobo C, Frazier W, Zheng P, Chang CH, Kelley D, Donohue JM (2018). Prescription Opioid Quality Measures Applied Among Pennsylvania Medicaid Enrollees. J Manag Care Spec Pharm, 24(9), 875-885. ()
    175. Jones AL, Mor MK, Haas GL, Gordon AJ, Cashy JP, Schaefer JH Jr, Hausmann LRM (2018). The Role of Primary Care Experiences in Obtaining Treatment for Depression. J Gen Intern Med, 33(8), 1366-1373. ()
    176. Williams EC, McGinnis KA, Bobb JF, Rubinsky AD, Lapham GT, Skanderson M, Catz SL, Bensley KM, Richards JE, Bryant KJ, Edelman EJ, Satre DD, Marshall BDL, Kraemer KL, Blosnich JR, Crystal S, Gordon AJ, Fiellin DA, Justice AC, Bradley KA (2018). Changes in alcohol use associated with changes in HIV disease severity over time: A national longitudinal study in the Veterans Aging Cohort. Drug Alcohol Depend, 189, 21-29. ()
    177. Radomski TR, Bixler FR, Zickmund SL, Roman KM, Thorpe CT, Hale JA, Sileanu FE, Hausmann LRM, Thorpe JM, Suda KJ, Stroupe KT, Gordon AJ, Good CB, Fine MJ, Gellad WF (2018). Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study. J Gen Intern Med, 33(8), 1253-1259. ()
    178. Jones AL, Hausmann LRM, Kertesz S, Suo Y, Cashy JP, Mor MK, Schaefer JH Jr, Gundlapalli AV, Gordon AJ (2018). Differences in Experiences With Care Between Homeless and Nonhomeless Patients in Veterans Affairs Facilities With Tailored and Nontailored Primary Care Teams. Med Care, 56(7), 610-618. ()
    179. Blosnich JR, Cashy J, Gordon AJ, Shipherd JC, Kauth MR, Brown GR, Fine MJ (2018). Using clinician text notes in electronic medical record data to validate transgender-related diagnosis codes. J Am Med Inform Assoc, 25(7), 905-908. ()
    180. Lin LA, Lofwall MR, Walsh SL, Gordon AJ, Knudsen HK (2018). Perceptions and practices addressing diversion among US buprenorphine prescribers. Drug Alcohol Depend, 186, 147-153. ()
    181. Adams JW, Bryant KJ, Edelman EJ, Fiellin DA, Gaither JR, Gordon AJ, Gordon KS, Kraemer KL, Mimiaga MJ, Operario D, Tate JP, van den Berg JJ, Justice AC, Marshall BDL (2018). Association of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men. AIDS Behav, 22(4), 1341-1351. ()
    182. Eyawo O, McGinnis KA, Justice AC, Fiellin DA, Hahn JA, Williams EC, Gordon AJ, Marshall BDL, Kraemer KL, Crystal S, Gaither JR, Edelman EJ, Bryant KJ, Tate JP, VACS Project team (2018). Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected. J Acquir Immune Defic Syndr, 77(2), 135-143. ()
    183. Gellad WF, Thorpe JM, Zhao X, Thorpe CT, Sileanu FE, Cashy JP, Hale JA, Mor MK, Radomski TR, Hausmann LRM, Donohue JM, Gordon AJ, Suda KJ, Stroupe KT, Hanlon JT, Cunningham FE, Good CB, Fine MJ (2018). Impact of Dual Use of Department of Veterans Affairs and Medicare Part D Drug Benefits on Potentially Unsafe Opioid Use. Am J Public Health, 108(2), 248-255. ()
    184. Bensley KM, McGinnis KA, Fiellin DA, Gordon AJ, Kraemer KL, Bryant KJ, Edelman EJ, Crystal S, Gaither JR, Korthuis PT, Marshall BDL, Ornelas IJ, Chan KCG, Dombrowski JC, Fortney JC, Justice AC, Williams EC (2018). Racial/ethnic differences in the association between alcohol use and mortality among men living with HIV. Addict Sci Clin Pract, 13(1), 2. ()
    185. Gordon AJ (2018). Abstracts presented at the International Society of Addiction Medicine (ISAM) 19th Annual Meeting, Abu Dhabi, United Arab Emirates, October 2017. Subst Abus, 39(1), 2. ()
    186. Gordon AJ (2018). Abstracts presented at the Association for Medical Education and Research in Substance Abuse (AMERSA) 41st Annual Conference, Washington, DC, USA, November 2017. Subst Abus, 39(1), 1. ()
    187. Stein BD, Dick AW, Sorbero M, Gordon AJ, Burns RM, Leslie DL, Pacula RL (2018). A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Subst Abus, 39(4), 419-425. ()
    188. Wyse JJ, Gordon AJ, Dobscha SK, Morasco BJ, Tiffany E, Drexler K, Sandbrink F, Lovejoy TI (2018). Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Subst Abus, 39(2), 139-144. ()
    189. Jones AL, Thomas R, Hedayati DO, Saba SK, Conley J, Gordon AJ (2018). Patient predictors and utilization of health services within a medical home for homeless persons. Subst Abus, 39(3), 354-360. ()
    190. Smid M, Gordon AJ, Plumb S, Plumb J (2018). Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstet Gynecol, 131(1), 163-164. ()
    191. Valenstein-Mah H, Hagedorn H, Kay CL, Christopher ML, Gordon AJ (2018). Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Subst Abus, 39(3), 286-288. ()
    192. Cochran G, McCarthy R, Gordon AJ, Tarter RE (2017). Opioid medication misuse among unhealthy drinkers. Drug Alcohol Depend, 179, 13-17. ()
    193. Sestito SF, Rodriguez KL, Saba SK, Conley JW, Mitchell MA, Gordon AJ (2017). Homeless veterans' experiences with substance use, recovery, and treatment through photo elicitation. Subst Abus, 38(4), 422-431. ()
    194. Bukowski LA, Blosnich J, Shipherd JC, Kauth MR, Brown GR, Gordon AJ (2017). Exploring Rural Disparities in Medical Diagnoses Among Veterans With Transgender-related Diagnoses Utilizing Veterans Health Administration Care. Med Care, 55 Suppl 9 Suppl 2, S97-S103. ()
    195. Frazier W, Cochran G, Lo-Ciganic WH, Gellad WF, Gordon AJ, Chang CH, Donohue JM (2017). Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid. JAMA, 318(8), 750-752. ()
    196. Mundkur ML, Gordon AJ, Kertesz SG (2017). Will strict limits on opioid prescription duration prevent addiction? Advocating for evidence-based policymaking. Subst Abus, 38(3), 237-238. ()
    197. Cochran G, Gordon AJ, Gellad WF, Chang CH, Lo-Ciganic WH, Lobo C, Cole E, Frazier W, Zheng P, Kelley D, Donohue JM (2017). Medicaid prior authorization and opioid medication abuse and overdose. Am J Manag Care, 23(5), e164-e171. ()
    198. Jones AL, Hausmann LRM, Haas GL, Mor MK, Cashy JP, Schaefer JH, Gordon AJ (2017). A national evaluation of homeless and nonhomeless veterans' experiences with primary care. Psychol Serv, 14(2), 174-183. ()
    199. Pringle JL, Kearney SM, Rickard-Aasen S, Campopiano MM, Gordon AJ (2017). A statewide screening, brief intervention, and referral to treatment (SBIRT) curriculum for medical residents: Differential implementation strategies in heterogeneous medical residency programs. Subst Abus, 38(2), 161-167. ()
    200. Levy S, Seale JP, Osborne VA, Kraemer KL, Alford DP, Baxter J, Finnell DS, Kunins H, Walley AY, Lewis DC, MacLane-Baeder D, Gordon AJ (2017). The Surgeon General's Facing Addiction report: An historic document for health care. Subst Abus, 38(2), 122. ()
    201. Gordon AJ, Harding JD Jr (2017). From education to practice: Addressing opioid misuse through health care provider training: A special issue of Substance Abuse journal. Subst Abus, 38(2), 119-121. ()
    202. Becker WC, Gordon K, Edelman EJ, Kerns RD, Crystal S, Dziura JD, Fiellin LE, Gordon AJ, Goulet JL, Justice AC, Fiellin DA (2017). Erratum to: Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV. AIDS Behav, 21(4), 1228. ()
    203. Blosnich JR, Marsiglio MC, Dichter ME, Gao S, Gordon AJ, Shipherd JC, Kauth MR, Brown GR, Fine MJ (2017). Impact of Social Determinants of Health on Medical Conditions Among Transgender Veterans. Am J Prev Med, 52(4), 491-498. ()
    204. Cochran G, Gordon AJ, Lo-Ciganic WH, Gellad WF, Frazier W, Lobo C, Chang CH, Zheng P, Donohue JM (2017). An Examination of Claims-based Predictors of Overdose from a Large Medicaid Program. Med Care, 55(3), 291-298. ()
    205. Stein BD, Mendelsohn J, Gordon AJ, Dick AW, Burns RM, Sorbero M, Shih RA, Liccardo Pacula R (2017). Opioid analgesic and benzodiazepine prescribing among Medicaid-enrollees with opioid use disorders: The influence of provider communities. J Addict Dis, 36(1), 14-22. ()
    206. Mitchell MA, Broyles LM, Pringle JL, Kraemer KL, Childers JW, Buranosky RA, Gordon AJ (2017). Education for the mind and the heart? Changing residents' attitudes about addressing unhealthy alcohol use. Subst Abus, 38(1), 40-42. ()
    207. Gordon AJ (2017). The 40th annual meeting of AMERSA: Highlights, abstracts, and awards. Subst Abus, 38(1), 1. ()
    208. Gordon AJ (2017). Abstracts of the 18th Annual Meeting of the International Society of Addiction Medicine (ISAM)-2016. Subst Abus, 38(1), 2. ()
    209. Jones AL, Mor MK, Cashy JP, Gordon AJ, Haas GL, Schaefer JH Jr, Hausmann LR (2016). Racial/Ethnic Differences in Primary Care Experiences in Patient-Centered Medical Homes among Veterans with Mental Health and Substance Use Disorders. J Gen Intern Med, 31(12), 1435-1443. ()
    210. Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, John Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodriguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Perez-Hoyos S, Jarrin I, Guest JL, DArminio Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernan MA (2016). Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. Int J Epidemiol, 45(6), 2038-2049. ()
    211. McGinnis KA, Tate JP, Williams EC, Skanderson M, Bryant KJ, Gordon AJ, Kraemer KL, Maisto SA, Crystal S, Fiellin DA, Justice AC (2016). Comparison of AUDIT-C collected via electronic medical record and self-administered research survey in HIV infected and uninfected patients. Drug Alcohol Depend, 168, 196-202. ()
    212. Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerd M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BD (2016). Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study. Addiction, 111(11), 2021-2031. ()
    213. Edelman EJ, Gordon KS, Tate JP, Becker WC, Bryant K, Crothers K, Gaither JR, Gibert CL, Gordon AJ, Marshall B, Rodriguez-Barradas MC, Samet JH, Skanderson M, Justice AC, Fiellin DA (2016). The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy. HIV Med, 17(10), 728-739. ()
    214. Narayanan AK, Harding JD Jr, Saba SK, Conley J, Gordon AJ Md Mph (2016). Left, right, and meeting in the middle: Addressing addiction is something we can agree about. Subst Abus, 37(4), 495-497. ()
    215. Stringfellow EJ, Kim TW, Gordon AJ, Pollio DE, Grucza RA, Austin EL, Johnson NK, Kertesz SG (2016). Substance use among persons with homeless experience in primary care. Subst Abus, 37(4), 534-541. ()
    216. Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ (2016). Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment. JAMA, 316(11), 1211-1212. ()
    217. Watson R, Morris J, Isitt J, Barrio P, Ortega L, Gual A, Conner K, Stecker T, Maisto S, Paroz S, Graap C, Grazioli VS, Daeppen JB, Collins SE, Bertholet N, McNeely J, Kushnir V, Cunningham JA, Crombie IK, Cunningham KB, Irvine L, Williams B, Sniehotta FF, Norrie J, Melson A, Jones C, Briggs A, Rice P, Achison M, McKenzie A, Dimova E, Slane PW, Grazioli VS, Collins SE, Paroz S, Graap C, Daeppen JB, Baggio S, Dupuis M, Studer J, Gmel G, Magill M, Grazioli VS, Tait RJ, Teoh L, Kelty E, Geelhoed E, Mountain D, Hulse GK, Renko E, Mitchell SG, Lounsbury D, Li Z, Schwartz RP, Gryczynski J, Kirk AS, Oros M, Hosler C, Dusek K, Brown BS, Finnell DS, Holloway A, Wu LT, Subramaniam G, Sharma G, Wallhed Finn S, Andreasson S, Dvorak RD, Kramer MP, Stevenson BL, Sargent EM, Kilwein TM, Harris SK, Sherritt L, Copelas S, Knight JR, The Partnership for Adolescent Substance Use Research, Mdege ND, McCambridge J, Bischof G, Bischof A, Freyer-Adam J, Rumpf HJ, Fitzgerald N, Schlin L, Toner P, Bhnke JR, Veach LJ, Currin O, Dongre LZ, Miller PR, White E, Williams EC, Lapham GT, Bobb JJ, Rubinsky AD, Catz SL, Shortreed S, Bensley KM, Bradley KA, Milward J, Deluca P, Khadjesari Z, Watson R, Fincham-Campbell S, Drummond C, Angus K, Bauld L, Baumann S, Haberecht K, Schnuerer I, Meyer C, Rumpf HJ, John U, Gaertner B, Barrault-Couchouron M, Bracocha M, Allafort V, Barthlmy V, Bonnefoi H, Bussires E, Garguil V, Auriacombe M, Saint-Jacques M, Dorval M, MBailara K, Segura-Garcia L, Ibaez-Martinez N, Mendive-Arbeloa JM, Anoro-Perminger M, Diaz-Gallego P, Piar-Mateos MA, Colom-Farran J, Deligianni M, Yersin B, Adam A, Weisner C, Chi F, Lu W, Sterling S, Kraemer KL, McGinnis KA, Fiellin DA, Skanderson M, Gordon AJ, Robbins J, Zickmund S, Korthuis PT, Edelman EJ, Hansen NB, Cutter CJ, Dziura J, Fiellin LE, OConnor PG, Maisto SA, Bedimo R, Gilbert C, Marconi VC, Rimland D, Rodriguez-Barradas M, Simberkoff M, Justice AC, Bryant KJ, Berman AH, Shorter GW, Bray JW, Barbosa C, Johansson M, Hester R, Campbell W, Souza Formigoni MLO, Andrade ALM, Sartes LMA, Sundstrm C, Ek N, Kraepelien M, Kaldo V, Fahlke C, Hernandez L, Becker SJ, Jones RN, Graves HR, Spirito A, Diestelkamp S, Wartberg L, Arnaud N, Thomasius R, Gaume J, Grazioli V, Fortini C, Malan Z, Mash B, Everett-Murphy K, Grazioli VS, Studer J, Mohler-Kuo M, Bertholet N, Gmel G, Doi L, Cheyne H, Jepson R, Luna V, Echeverria L, Morales S, Barroso T, Abreu, Aguiar C, Stewart D, Abreu A, Brites RM, Jomar R, Marinho G, Parreira P, Seale JP, Johnson JA, Henry D, Chalmers S, Payne F, Tuck L, Morris A, Gonalves C, Besser B, Casajuana C, Lpez-Pelayo H, Balcells MM, Teixid L, Miquel L, Colom J, Hepner KA, Hoggatt KJ, Bogart A, Paddock SM, Hardoon SL, Petersen I, Hamilton FL, Nazareth I, White IR, Marston L, Wallace P, Godfrey C, Murray E, Sovinov H, Csmy L (2016). Proceedings of the 13th annual conference of INEBRIA. Addict Sci Clin Pract, 11(Suppl 1), 13. ()
    218. Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Lo Re V 3rd, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA (2016). Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. J Subst Abuse Treat, 68, 62-7. ()
    219. Clark DB, Martin CS, Chung T, Gordon AJ, Fiorentino L, Tootell M, Rubio DM (2016). Screening for Underage Drinking and Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Alcohol Use Disorder in Rural Primary Care Practice. J Pediatr, 173, 214-20. ()
    220. Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, Donohue JM (2016). Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction, 111(5), 892-902. ()
    221. Gordon A, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Donohue JM (2016). Treatment Quality for Buprenorphine Care: The Pot at the End of the Rainbow. J Addict Med, 10(3), 210-1. ()
    222. Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, Edelman EJ, Fiellin LE, Freiberg MS, Gordon AJ, Kraemer KL, Marshall BD, Williams EC, Fiellin DA (2016). Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend, 161, 95-103. ()
    223. McGinnis KA, Fiellin DA, Tate JP, Cook RL, Braithwaite RS, Bryant KJ, Edelman EJ, Gordon AJ, Kraemer KL, Maisto SA, Justice AC (2016). Number of Drinks to "Feel a Buzz" by HIV Status and Viral Load in Men. AIDS Behav, 20(3), 504-11. ()
    224. Blosnich JR, Marsiglio MC, Gao S, Gordon AJ, Shipherd JC, Kauth M, Brown GR, Fine MJ (2016). Mental Health of Transgender Veterans in US States With and Without Discrimination and Hate Crime Legal Protection. Am J Public Health, 106(3), 534-40. ()
    225. Becker WC, Gordon K, Edelman EJ, Kerns RD, Crystal S, Dziura JD, Fiellin LE, Gordon AJ, Goulet JL, Justice AC, Fiellin DA (2016). Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV. AIDS Behav, 20(3), 679-86. ()
    226. Cochran G, Gordon AJ, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter R (2016). Developing a framework of care for opioid medication misuse in community pharmacy. Res Social Adm Pharm, 12(2), 293-301. ()
    227. Steward J, Holt CL, Pollio DE, Austin EL, Johnson N, Gordon AJ, Kertesz SG (2016). Priorities in the primary care of persons experiencing homelessness: convergence and divergence in the views of patients and provider/experts. Patient Prefer Adherence, 10, 153-8. ()
    228. Depp TB, McGinnis KA, Kraemer K, Akgun KM, Edelman EJ, Fiellin DA, Butt AA, Crystal S, Gordon AJ, Freiberg M, Gibert CL, Rimland D, Bryant KJ, Crothers K (2016). Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients. AIDS, 30(3), 455-63. ()
    229. Korthuis PT, McGinnis KA, Kraemer KL, Gordon AJ, Skanderson M, Justice AC, Crystal S, Goetz MB, Gibert CL, Rimland D, Fiellin LE, Gaither JR, Wang K, Asch SM, McInnes DK, Ohl ME, Bryant K, Tate JP, Duggal M, Fiellin DA (2016). Quality of HIV Care and Mortality Rates in HIV-Infected Patients. Clin Infect Dis, 62(2), 233-239. ()
    230. Lan CW, Fiellin DA, Barry DT, Bryant KJ, Gordon AJ, Edelman EJ, Gaither JR, Maisto SA, Marshall BD (2016). The epidemiology of substance use disorders in US Veterans: A systematic review and analysis of assessment methods. Am J Addict, 25(1), 7-24. ()
    231. Burns RM, Pacula RL, Bauhoff S, Gordon AJ, Hendrikson H, Leslie DL, Stein BD (2016). Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013. Subst Abus, 37(1), 63-9. ()
    232. Mitchell MA, Hedayati DO, Rodriguez KL, True G, Balbale SN, Gordon AJ, Conley JW, Broyles LM (2016). Logistical Lessons Learned in Designing and Executing a Photo-Elicitation Study in the Veterans Health Administration.
    233. Gordon AJ, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Kelley D, Donohue JM (2015). Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program. J Addict Med, 9(6), 470-7. ()
    234. Stein BD, Pacula RL, Gordon AJ, Burns RM, Leslie DL, Sorbero MJ, Bauhoff S, Mandell TW, Dick AW (2015). Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties. Milbank Q, 93(3), 561-83. ()
    235. Jones AL, Hanusa BH, Appelt CJ, Haas GL, Gordon AJ, Hausmann LR (2015). Racial Differences in Veterans' Satisfaction With Addiction Treatment Services. J Addict Med, 9(5), 383-90. ()
    236. Blosnich JR, Gordon AJ, Fine MJ (2015). Associations of sexual and gender minority status with health indicators, health risk factors, and social stressors in a national sample of young adults with military experience. Ann Epidemiol, 25(9), 661-7. ()
    237. Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miro JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Perez-Hoyos S, Jarrin I, Jose S, Sabin C, Hernan MA (2015). Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV, 2(8), e335-43. ()
    238. Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie D, Stein BD (2015). Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11. Health Aff (Millwood), 34(6), 1028-34. ()
    239. Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, Moore BA, Tate J, Justice AC, Fiellin DA (2015). Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. J Acquir Immune Defic Syndr, 69(2), 223-33. ()
    240. Broyles LM, Wieland ME, Confer AL, DiNardo MM, Kraemer KL, Hanusa BH, Youk AO, Gordon AJ, Sevick MA (2015). Alcohol brief intervention for hospitalized veterans with hazardous drinking: protocol for a 3-arm randomized controlled efficacy trial. Addict Sci Clin Pract, 10, 13. ()
    241. Oslin DW, Leong SH, Lynch KG, Berrettini W, OBrien CP, Gordon AJ, Rukstalis M (2015). Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. JAMA Psychiatry, 72(5), 430-7. ()
    242. King JT Jr, Perkal MF, Rosenthal RA, Gordon AJ, Crystal S, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice AC (2015). Thirty-day postoperative mortality among individuals with HIV infection receiving antiretroviral therapy and procedure-matched, uninfected comparators. JAMA Surg, 150(4), 343-51. ()
    243. Marshall BD, Operario D, Bryant KJ, Cook RL, Edelman EJ, Gaither JR, Gordon AJ, Kahler CW, Maisto SA, McGinnis KA, van den Berg JJ, Zaller ND, Justice AC, Fiellin DA (2015). Drinking trajectories among HIV-infected men who have sex with men: a cohort study of United States veterans. Drug Alcohol Depend, 148, 69-76. ()
    244. Farmer CM, Lindsay D, Williams J, Ayers A, Schuster J, Cilia A, Flaherty MT, Mandell T, Gordon AJ, Stein BD (2015). Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. Subst Abus, 36(2), 209-16. ()
    245. Badejo OA, Chang CC, So-Armah KA, Tracy RP, Baker JV, Rimland D, Butt AA, Gordon AJ, Rinaldo CR Jr, Kraemer K, Samet JH, Tindle HA, Goetz MB, Rodriguez-Barradas MC, Bedimo R, Gibert CL, Leaf DA, Kuller LH, Deeks SG, Justice AC, Freiberg MS (2015). CD8+ T-cells count in acute myocardial infarction in HIV disease in a predominantly male cohort. Biomed Res Int, 2015, 246870. ()
    246. Cochran G, Woo B, Lo-Ciganic WH, Gordon AJ, Donohue JM, Gellad WF (2015). Defining Nonmedical Use of Prescription Opioids Within Health Care Claims: A Systematic Review. Subst Abus, 36(2), 192-202. ()
    247. Chrystal JG, Glover DL, Young AS, Whelan F, Austin EL, Johnson NK, Pollio DE, Holt CL, Stringfellow E, Gordon AJ, Kim TA, Daigle SG, Steward JL, Kertesz SG (2015). Experience of primary care among homeless individuals with mental health conditions. PLoS One, 10(2), e0117395. ()
    248. Stein BD, Gordon AJ, Dick AW, Burns RM, Pacula RL, Farmer CM, Leslie DL, Sorbero M (2015). Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat, 48(1), 104-11. ()
    249. Blosnich JR, Gordon AJ, Bossarte RM (2014). Suicidal ideation and mental distress among adults with military service history: results from 5 U.S. states, 2010. Am J Public Health, 104 Suppl 4, S595-602. ()
    250. Kertesz SG, Pollio DE, Jones RN, Steward J, Stringfellow EJ, Gordon AJ, Johnson NK, Kim TA, Daigle SG, Austin EL, Young AS, Chrystal JG, Davis LL, Roth DL, Holt CL (2014). Development of the Primary Care Quality-Homeless (PCQ-H) instrument: a practical survey of homeless patients' experiences in primary care. Med Care, 52(8), 734-42. ()
    251. Long JA, Wang A, Medvedeva EL, Eisen SV, Gordon AJ, Kreyenbuhl J, Marcus SC (2014). Glucose control and medication adherence among veterans with diabetes and serious mental illness: does collocation of primary care and mental health care matter? Diabetes Care, 37(8), 2261-7. ()
    252. Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Lo Re V 3rd (2014). Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis, 58(10), 1449-58. ()
    253. Gordon AJ, Galanter M, Khalsa JH (2014). Addressing addiction across borders: an international perspective on policies, scholarship, and collaboration. Subst Abus, 35(3), 290-1. ()
    254. McLellan AT, Starrels JL, Tai B, Gordon AJ, Brown R, Ghitza U, Gourevitch M, Stein J, Oros M, Horton T, Lindblad R, McNeely J (2014). Can Substance Use Disorders be Managed Using the Chronic Care Model? Review and Recommendations from a NIDA Consensus Group. Public Health Rev, 35(2). ()
    255. Gabrielian S, Gordon AJ, Gelberg L, Patel B, Manchanda R, Altman L, Andersen RM, Campell RA, Broyles LM, Conley J, Kertesz S (2014). Building primary care medical homes for homeless veterans at 3 VA facilities. Fed Pract, 31(10), 10-9.
    256. Gordon AJ, Conley JW, Gordon JM (2013). Medical consequences of marijuana use: a review of current literature. Curr Psychiatry Rep, 15(12), 419. ()
    257. Kertesz SG, Holt CL, Steward JL, Jones RN, Roth DL, Stringfellow E, Gordon AJ, Kim TW, Austin EL, Henry SR, Kay Johnson N, Shanette Granstaff U, OConnell JJ, Golden JF, Young AS, Davis LL, Pollio DE (2013). Comparing homeless persons' care experiences in tailored versus nontailored primary care programs. Am J Public Health, 103 Suppl 2, S331-9. ()
    258. Strobel B, McManus L, Leong S, Blow F, Slaymaker V, Berrettini W, Gordon AJ, OBrien C, Oslin D (2013). A cross-sectional study of attitudes about the use of genetic testing for clinical care among patients with an alcohol use disorder. Alcohol Alcohol, 48(6), 700-3. ()
    259. Harris AHS, Ellerbe L, Reeder RN, Bowe T, Gordon AJ, Hagedorn H, Oliva E, Lembke A, Kivlahan D, Trafton JA (2013). Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv, 10(4), 410-419. ()
    260. Ghose T, Fiellin DA, Gordon AJ, Metraux S, Goetz MB, Blackstock O, McInnes K, Rodriguez-Barradas MC, Justice AC (2013). Hazardous drinking and its association with homelessness among veterans in care. Drug Alcohol Depend, 132(1-2), 202-6. ()
    261. Del Re AC, Gordon AJ, Lembke A, Harris AH (2013). Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration. Addict Sci Clin Pract, 8(1), 12. ()
    262. Broyles LM, Kraemer KL, Kengor C, Gordon AJ (2013). A tailored curriculum of alcohol screening, brief intervention, and referral to treatment (SBIRT) for nurses in inpatient settings. J Addict Nurs, 24(3), 130-41. ()
    263. Oliva EM, Trafton JA, Harris AH, Gordon AJ (2013). Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse, 39(2), 103-7. ()
    264. Goulet JL, Brandt C, Crystal S, Fiellin DA, Gibert C, Gordon AJ, Kerns RD, Maisto S, Justice AC (2013). Agreement between electronic medical record-based and self-administered pain numeric rating scale: clinical and research implications. Med Care, 51(3), 245-50. ()
    265. Broyles LM, Conley JW, Harding JD Jr, Gordon AJ (2013). A scoping review of interdisciplinary collaboration in addictions education and training. J Addict Nurs, 24(1), 29-36; quiz 37-8. ()
    266. Broyles LM, Gordon AJ, Rodriguez KL, Hanusa BH, Kengor C, Kraemer KL (2013). Evaluation of a pilot training program in alcohol screening, brief intervention, and referral to treatment for nurses in inpatient settings. J Addict Nurs, 24(1), 8-19. ()
    267. Edelman EJ, Gordon K, Becker WC, Goulet JL, Skanderson M, Gaither JR, Brennan Braden J, Gordon AJ, Kerns RD, Justice AC, Fiellin DA (2013). Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med, 28(1), 82-90. ()
    268. Sayers SL, Gordon AJ, Streim JE, Thase M, Sweet R, Haas G, Goldstein G (2013). A conceptual framework of comorbidity for investigation in the context of psychiatric disturbance. Curr Psychiatry Rev, 9(2), 155-63.
    269. Korthuis PT, Fiellin DA, McGinnis KA, Skanderson M, Justice AC, Gordon AJ, Doebler DA, Asch SM, Fiellin LE, Bryant K, Gibert CL, Crystal S, Goetz MB, Rimland D, Rodriguez-Barradas MC, Kraemer KL (2012). Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr, 61(2), 171-8. ()
    270. Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernan MA (2012). The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS, 26(13), 1691-705. ()
    271. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M (2012). HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis, 55(1), 126-36. ()
    272. Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C (2012). The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend, 123(1-3), 72-8. ()
    273. Broyles LM, Rodriguez KL, Kraemer KL, Sevick MA, Price PA, Gordon AJ (2012). A qualitative study of anticipated barriers and facilitators to the implementation of nurse-delivered alcohol screening, brief intervention, and referral to treatment for hospitalized patients in a Veterans Affairs medical center. Addict Sci Clin Pract, 7, 7. ()
    274. Oliva EM, Harris AH, Trafton JA, Gordon AJ (2012). Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Drug Alcohol Depend, 122(3), 241-6. ()
    275. del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Perez-Hoyos S, Jarrin I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miro JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernan MA (2012). Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis, 54(9), 1364-72. ()
    276. Broyles LM, Rosenberger E, Hanusa BH, Kraemer KL, Gordon AJ (2012). Hospitalized patients' acceptability of nurse-delivered screening, brief intervention, and referral to treatment. Alcohol Clin Exp Res, 36(4), 725-31. ()
    277. King JT Jr, Gordon AJ, Perkal MF, Crystal S, Rosenthal RA, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice AC (2012). Disparities in rates of spine surgery for degenerative spine disease between HIV-infected and uninfected veterans. Spine (Phila Pa 1976), 37(7), 612-22. ()
    278. Pringle JL, Melczak M, Johnjulio W, Campopiano M, Gordon AJ, Costlow M (2012). Pennsylvania SBIRT Medical and Residency Training: developing, implementing, and evaluating an evidenced-based program. Subst Abus, 33(3), 292-7. ()
    279. Childers JW, Broyles LM, Hanusa BH, Kraemer KL, Conigliaro J, Spagnoletti C, McNeil M, Gordon AJ (2012). Teaching the teachers: faculty preparedness and evaluation of a retreat in screening, brief intervention, and referral to treatment. Subst Abus, 33(3), 272-7. ()
    280. Ghose T, Gordon AJ, Metraux S, Justice AC (2011). Mental illness and homelessness among veterans. Psychiatr Serv, 62(12), 1514-5. ()
    281. Gordon AJ, Ettaro L, Rodriguez KL, Mocik J, Clark DB (2011). Provider, patient, and family perspectives of adolescent alcohol use and treatment in rural settings. J Rural Health, 27(1), 81-90. ()
    282. Broyles LM, Gordon AJ, Sereika SM, Ryan CM, Erlen JA (2011). Predictive Utility of Brief Alcohol Use Disorders Identification Test (AUDIT) for human immunodeficiency virus antiretroviral medication nonadherence. Subst Abus, 32(4), 252-61. ()
    283. Broyles LM, Gordon AJ, Sereika SM, Ryan CM, Erlen JA (2011). Do words matter? Incongruent responses to inconsistently worded AUDIT-C alcohol screening instruments. Subst Abus, 32(4), 202-9. ()
    284. Oliva EM, Maisel NC, Gordon AJ, Harris AH (2011). Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep, 13(5), 374-81. ()
    285. Gordon AJ, Kavanagh G, Krumm M, Ramgopal R, Paidisetty S, Aghevli M, Goodman F, Trafton J, Liberto J (2011). Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav, 25(2), 215-24. ()
    286. Barry DT, Goulet JL, Kerns RK, Becker WC, Gordon AJ, Justice AC, Fiellin DA (2011). Nonmedical use of prescription opioids and pain in veterans with and without HIV. Pain, 152(5), 1133-1138. ()
    287. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA (2011). When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med, 154(8), 509-15. ()
    288. Goldstein G, Luther JF, Haas GL, Appelt CJ, Gordon AJ (2010). Factor structure and risk factors for the health status of homeless veterans. Psychiatr Q, 81(4), 311-23. ()
    289. Green TC, Kershaw T, Lin H, Heimer R, Goulet JL, Kraemer KL, Gordon AJ, Maisto SA, Day NL, Bryant K, Fiellin DA, Justice AC (2010). Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend, 110(3), 208-20. ()
    290. Gordon AJ, Haas GL, Luther JF, Hilton MT, Goldstein G (2010). Personal, Medical, and Healthcare Utilization Among Homeless Veterans Served by Metropolitan and Nonmetropolitan Veteran Facilities. Psychol Serv, 7(2), 65-74. ()
    291. Clark DB, Gordon AJ, Ettaro LR, Owens JM, Moss HB (2010). Screening and brief intervention for underage drinkers. Mayo Clin Proc, 85(4), 380-91. ()
    292. Cook RL, McGinnis KA, Samet JH, Fiellin DA, Rodriguez-Barradas MC, Kraemer KL, Gibert CL, Braithwaite RS, Goulet JL, Mattocks K, Crystal S, Gordon AJ, Oursler KK, Justice AC (2010). Erectile dysfunction drug receipt, risky sexual behavior and sexually transmitted diseases in HIV-infected and HIV-uninfected men. J Gen Intern Med, 25(2), 115-21. ()
    293. Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Perez-Hoyos S, Garcia de Olalla P, Hernan MA (2010). The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS, 24(1), 123-37. ()
    294. Goldstein G, Luther JF, Haas GL, Gordon AJ, Appelt C (2009). Comorbidity between psychiatric and general medical disorders in homeless veterans. Psychiatr Q, 80(4), 199-212. ()
    295. Gordon AJ, Geppert CMA, Saxon A, Cotton A, Bondurant T, Krumm M, Acquaviva MP, Trafton J (2009). Models for implementing buprenorphine treatment in the VHA. Fed Pract, 26(5), 48-57.
    296. Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andree T, McNicholas L (2008). Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict, 17(6), 459-62. ()
    297. Goldstein G, Luther JF, Jacoby AM, Haas GL, Gordon AJ (2008). A Taxonomy of medical comorbidity for veterans who are homeless. J Health Care Poor Underserved, 19(3), 991-1005. ()
    298. Maisto SA, Conigliaro JC, Gordon AJ, McGinnis KA, Justice AC (2008). An experimental study of the agreement of self-administration and telephone administration of the Timeline Followback interview. J Stud Alcohol Drugs, 69(3), 468-71. ()
    299. Walley AY, Phillips KA, Gordon AJ (2008). The patients in recovery (PIR) perspective: teaching physicians about methamphetamine. Subst Abus, 29(4), 61-4. ()
    300. Mays KL, Clark DL, Gordon AJ (2008). Treating addiction with tunes: a systematic review of music therapy for the treatment of patients with addictions. Subst Abus, 29(4), 51-9. ()
    301. Goldstein G, Luther JF, Jacoby AM, Haas GL, Gordon AJ (2008). A preliminary classification system for homeless Veterans with mental illness. Psychol Serv, 5, 36-48.
    302. Gordon AJ, Trafton JA, Saxon AJ, Gifford AL, Goodman F, Calabrese VS, McNicholas L, Liberto J (2007). Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug Alcohol Depend, 90(2-3), 292-6. ()
    303. Sevick MA, Napolitano MA, Papandonatos GD, Gordon AJ, Reiser LM, Marcus BH (2007). Cost-effectiveness of alternative approaches for motivating activity in sedentary adults: results of Project STRIDE. Prev Med, 45(1), 54-61. ()
    304. Gordon AJ, Montlack ML, Freyder P, Johnson D, Bui T, Williams J (2007). The Allegheny initiative for mental health integration for the homeless: integrating heterogeneous health services for homeless persons. Am J Public Health, 97(3), 401-5. ()
    305. Gordon AJ, McGinnis KA, Conigliaro J, Rodriguez-Barradas MC, Rabeneck L, Justice AC (2006). Associations between alcohol use and homelessness with healthcare utilization among human immunodeficiency virus-infected veterans. Med Care, 44(8 Suppl 2), S37-43. ()
    306. Cook RL, McGinnis KA, Kraemer KL, Gordon AJ, Conigliaro J, Maisto SA, Samet JH, Crystal S, Rimland D, Bryant KJ, Braithwaite RS, Justice AC (2006). Intoxication before intercourse and risky sexual behavior in male veterans with and without human immunodeficiency virus infection. Med Care, 44(8 Suppl 2), S31-6. ()
    307. Conigliaro J, Justice AC, Gordon AJ, Bryant K, VACS Alcohol and Behavior Change Research Group (2006). Role of alcohol in determining human immunodeficiency virus (HIV)-relevant outcomes: A conceptual model to guide the implementation of evidence-based interventions into practice. Med Care, 44(8 Suppl 2), S1-6. ()
    308. Kraemer KL, McGinnis KA, Skanderson M, Cook R, Gordon A, Conigliaro J, Shen Y, Fiellin DA, Justice AC (2006). Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans. Med Care, 44(8 Suppl 2), S44-51. ()
    309. Gordon AJ, Olstein J, Conigliaro J (2006). Identification and treatment of alcohol use disorders in the perioperative period. Postgrad Med, 119(2), 46-55. ()
    310. Paidisetty S, Gordon AJ (2006). Pharmacologic management of alcohol use disorders in the primary care setting. J Clin Outcomes Manag, 13(11), 628-46.
    311. Gordon AJ (2006). Screening the drinking: identifying problem alcohol consumption in primary care settings. 6(3), 137-47.
    312. Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Cook RL, Gordon A, Bridges MW, Seiler JF, Justice AC (2005). A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res, 29(7), 1190-7. ()
    313. Mays DM, Gordon AJ, Kelly ME, Forman SD (2005). Violent criminal behavior and perspectives on treatment of criminality in opiate treatment. Subst Abus, 26(2), 33-42. ()
    314. Conigliaro J, Madenwald T, Bryant K, Braithwaite S, Gordon A, Fultz SL, Maisto S, Samet J, Kraemer K, Cook R, Day N, Roach D, Richey S, Justice A (2004). The Veterans Aging Cohort Study: observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus-infected veterans. Alcohol Clin Exp Res, 28(2), 313-21. ()
    315. Gordon AJ, Saitz R (2004). Identification and treatment of alcohol use disorders in primary care. J Clin Outcomes Manag, 11(7), 444-60.
    316. Conigliaro J, Gordon AJ, McGinnis KA, Rabeneck L, Justice AC, Veterans Aging Cohort 3-Site Study (2003). How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? J Acquir Immune Defic Syndr, 33(4), 521-5. ()
    317. Gordon AJ, Conigliaro J, Maisto SA, McNeil M, Kraemer KL, Kelley ME (2003). Comparison of consumption effects of brief interventions for hazardous drinking elderly. Subst Use Misuse, 38(8), 1017-35. ()
    318. Gordon AJ, Macpherson DS (2003). Guideline chaos: conflicting recommendations for preoperative cardiac assessment. Am J Cardiol, 91(11), 1299-303. ()
    319. Kraemer KL, Maisto SA, Conigliaro J, McNeil M, Gordon AJ, Kelley ME (2002). Decreased alcohol consumption in outpatient drinkers is associated with improved quality of life and fewer alcohol-related consequences. J Gen Intern Med, 17(5), 382-6. ()
    320. Gordon AJ, Maisto SA, McNeil M, Kraemer KL, Conigliaro RL, Kelley ME, Conigliaro J (2001). Three questions can detect hazardous drinkers. J Fam Pract, 50(4), 313-20. ()
    321. Gordon AJ, Wentz CM, Gibbon JL, Mason AD, Freyder PJ, OToole TP (2001). Relationships between patient characteristics and unsuccessful substance abuse detoxification. J Addict Dis, 20(2), 41-53. ()
    322. Gordon AJ (1999). Residency and volunteerism: not mutually exclusive. Pa Med, 102(6), 13. ()
    323. Gordon AJ (1999). Clinical evidence: marijuana a useful medicine. Pa Med, 102(1), 3.

    Review

    1. Incze MA, Kelley AT, James H, Nolan S, Stofko A, Fordham C, Gordon AJ (2024). Post-hospitalization Care Transition Strategies for Patients with Substance Use Disorders: A Narrative Review and Taxonomy. [Review]. J Gen Intern Med, 39(5), 837-846. ()
    2. Tan CJ, Shufelt T, Behan E, Chantara J, Koomsri C, Gordon AJ, Chaiyakunapruk N, Dhippayom T (2023). Comparative effectiveness of psychosocial interventions in adults with harmful use of alcohol: a systematic review and network meta-analysis. [Review]. Addiction. ()
    3. Hickey TR, Meeks T, Oxentine H, Park DC, Abelleira A, Edens E, Gordon AJ, Acampora G (2023). Perioperative Management of Extended-Release Buprenorphine: A Narrative Review and Case Series. [Review]. Subst Abus, 44(1), 96-103. ()
    4. Kelley AT, Incze MA, Baylis JD, Calder SG, Weiner SJ, Zickmund SL, Jones AL, Vanneman ME, Conroy MB, Gordon AJ, Bridges JFP (2023). Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice. [Review]. Subst Abus, 43(1), 1286-1299. ()
    5. Wyse JJ, Mackey K, Lovejoy TI, Kansagara D, Tuepker A, Gordon AJ, Todd Korthuis P, Herreid-ONeill A, Williams B, Morasco BJ (2022). Expanding access to medications for opioid use disorder through locally-initiated implementation. [Review]. Addict Sci Clin Pract, 17(1), 32. ()
    6. Gordon AJ, Bertholet N, McNeely J, Starrels JL, Tetrault JM, Walley AY (2013). 2013 Update in addiction medicine for the generalist. [Review]. Addict Sci Clin Pract, 8, 18. ()
    7. Rastegar DA, Kunins HV, Tetrault JM, Walley AY, Gordon AJ (2013). 2012 Update in addiction medicine for the generalist. [Review]. Addict Sci Clin Pract, 8, 6. ()
    8. Gordon AJ, Kunins HV, Rastegar DA, Tetrault JM, Walley AY (2011). Update in addiction medicine for the generalist. [Review]. J Gen Intern Med, 26(1), 77-82. ()
    9. Gordon AJ, Fiellin DA, Friedmann PD, Gourevitch MN, Kraemer KL, Arnsten JH, Saitz R (2008). Update in addiction medicine for the primary care clinician. [Review]. J Gen Intern Med, 23(12), 2112-6. ()
    10. Gordon AJ, Sullivan LE, Alford DP, Arnsten JH, Gourevitch MN, Kertesz SG, Kunins HV, Merrill JO, Samet JH, Fiellin DA (2007). Update in addiction medicine for the generalist. [Review]. J Gen Intern Med, 22(8), 1190-4. ()

    Book

    1. Gordon AJ, with contributing authors Gordon JM, Striebel J, Hilton M, Carl K, Maher M (2010). Physical Illness and Drugs of Abuse: A Review of the Evidence. Cambridge, UK: Cambridge 㽶Ƶ Press.
    2. Strain EC Chair, Gordon AJ, Johnson BA, McCaul ME, Saxon A, Swift R, Zweben A (2009). Incorporating Alcohol Pharmacotherapies Into Medical Practice. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). ()

    Book Chapter

    1. Haibach JP, DiNapoli EA, Finnell DS, Kasckow JW, Gordon AJ (2017). Chapter 15: Motivational Interviewing: its role for the management of mental disorders in primary care. In Carvalho AF, McIntyre RS (Eds.), Mental Disorders in Primary Care: A Guide to their Evaluation and Management (1st). Oxford, England: Oxford 㽶Ƶ Press.
    2. Gordon AJ, Conley JW, Gordon JM (2015). Physical diseases and addictive disorders: associations and implications. In Sartorius N, Holt RIG, Maj M (Eds.), Comorbidity of Mental and Physical Disorders (Vol. 179, pp. 114-28). Basal, Switzerland: Karger Publishers.
    3. Gordon AJ, Krumm MM (2013). Buprenorphine for opioid dependence. In Miller PM (Ed.), Interventions for Addiction: Comprehensive Addictive Behaviors and Disorders (pp. 417-26). San Diego, CA: Academic Press.
    4. Gordon AJ, Gordon JM, Broyles LM (2013). Medical consequences of unhealthy alcohol use. In Saitz R (Ed.), Addressing Unhealthy Alcohol Use in Primary Care (pp. 107-18). New York: Springer-Verlag.
    5. Gordon AJ (2006). Alcohol and substance abuse in the perioperative period. In Cohn SL, Smetana GW, Weed H (Eds.), Just the Facts in Perioperative Medicine (pp. 231-8). New York, NY: McGraw Hill.
    6. Gordon AJ, Conigliaro J, Fiellin D (2004). Selective methods used in alcohol research: screening in primary care—methods and approaches. In Preedy VR, Watson RR (Eds.), Comprehensive Handbook of Alcohol-Related Pathology (pp. 1327-45). Burlington, MA: Elsevier.

    Editorial

    1. Hayes CJ, Cucciare MA, Martin BC, Hudson TJ, Bush K, Lo-Ciganic W, Yu H, Charron E, Gordon AJ (2022). Using data science to improve outcomes for persons with opioid use disorder. Subst Abus, 43(1), 956-963. ()
    2. Incze MA, Kelley AT, Gordon AJ (2021). Improving Opioid Use Disorder Treatment through Quality Assessment. J Gen Intern Med, 36(9), 2820-2822. ()
    3. Becker WC, Krebs EE, Edmond SN, Lin LA, Sullivan MD, Weiss RD, Gordon AJ (2020). A Research Agenda for Advancing Strategies to Improve Opioid Safety: Findings from a VHA State of the Art Conference. J Gen Intern Med, 35(Suppl 3), 978-982. ()
    4. Cochran G, Bruneau J, Cox N, Gordon AJ (2020). Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. Subst Abus, 41(3), 269-274. ()
    5. Gordon AJ (2019). The International Society of Addiction Medicine (ISAM): Abstracts from its 2018 annual meeting, Busan, Korea. Subst Abus, 40(1), 1. ()
    6. Gordon AJ (2019). AMERSA's 42nd annual meeting: Highlights, abstracts and awards, and an appreciation to our peer reviewers. Subst Abus, 40(1), 2-3. ()
    7. Gordon AJ (2017). Foreword: Ethnographic methods in the study of ethnicity in substance abuse. J Ethn Subst Abuse, 17(1), 1-6. ()
    8. Gordon AJ MD MPH, Oliva EM (2019). Applying and advancing best practices in opioid use disorder and addiction treatment: Introduction to the special issue on implementation science and quality improvement scholarship. Subst Abus, 39(2), 125-128. ()
    9. Frank JW, Wakeman SE, Gordon AJ (2018). No end to the crisis without an end to the waiver. Subst Abus, 39(3), 263-265. ()
    10. Gordon AJ, Saba SK (2016). Confronting the opioid epidemic through publication, promotion, and dissemination of evidence-based addiction scholarship. Subst Abus, 37(3), 379-380. ()
    11. Kaminer Y, Gordon AJ (2016). The blind side of addiction: A call for increased awareness of developmentally informed youth addiction scholarship. Subst Abus, 37(2), 276-7. ()
    12. Gordon AJ (2016). Integrating policy and research into addiction practice, AMERSA abstracts, and an appreciation to our reviewers. Subst Abus, 37(2), 271-5. ()
    13. Binswanger IA, Gordon AJ (2016). From risk reduction to implementation: Addressing the opioid epidemic and continued challenges to our field. Subst Abus, 37(1), 1-3. ()
    14. Tierney M, Finnell DS, Naegle MA, LaBelle C, Gordon AJ (2015). Advanced Practice Nurses: Increasing Access to Opioid Treatment by Expanding the Pool of Qualified Buprenorphine Prescribers. Subst Abus, 36(4), 389-92. ()
    15. Gordon AJ, Haibach J (2015). Screening and Intervening on Alcohol and Other Drug Use in General Wellness Programs: Challenges and Opportunities. Subst Abus, 36(3), 255-6. ()
    16. Gordon AJ, Jenkins JA (2015). The Time Is Now: The Role of Pharmacotherapies in Expanding Treatment for Opioid Use Disorder. Subst Abus, 36(2), 127-8. ()
    17. Jenkins JA, Gordon AJ (2015). Substance use disorder prevention and treatment in stigmatized patient populations: ripe for innovation. Subst Abus, 36(1), 1-2. ()
    18. Gordon AJ, Jenkins JA, Galanter M (2015). International addiction scholarship: promise, progress, and results from the annual meeting of the International Society of Addiction Medicine. Subst Abus, 36(2), 129-30.
    19. Jenkins JA, Alford DP, Gordon AJ (2015). Building connections and bridging interdisciplinary leadership in addictions: 2014 AMERSA annual conference and a thank you to reviewers. Subst Abus, 36(2), 131-4.
    20. Kaminer Y, Gordon AJ (2014). It is getting late here early: youth substance abuse theory and practice. Subst Abus, 35(4), 329-30. ()
    21. Broyles LM, Binswanger IA, Jenkins JA, Finnell DS, Faseru B, Cavaiola A, Pugatch M, Gordon AJ (2014). Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Subst Abus, 35(3), 217-21. ()
    22. Gordon AJ (2014). Maternal and neonatal morbidity: dual harms associated with addiction in pregnancy. Subst Abus, 35(1), 1-2. ()
    23. Jenkins JA, Gordon AJ (2014). Advancing the peer review process: a multifaceted approach to improving quality. Subst Abus, 35(2), 105-7. ()
    24. Gordon AJ, Broyles LM (2014). A physician-centered approach to addiction identification and treatment misses the opportunity for interdisciplinary solutions. Subst Abus, 35(2), 108-9. ()
    25. Gordon AJ (2013). Substance abuse journal: new beginnings. Subst Abus, 34(4), 339-41. ()
    26. Gordon AJ, Alford DP (2012). Screening, brief intervention, and referral to treatment (SBIRT) curricular innovations: addressing a training gap. Subst Abus, 33(3), 227-30. ()
    27. Broyles LM, Gordon AJ (2010). SBIRT implementation: moving beyond the interdisciplinary rhetoric. Subst Abus, 31(4), 221-3. ()

    Letter

    1. Gustavson AM, Hagedorn HJ, Jesser LE, Kenny ME, Clothier BA, Bounthavong M, Ackland PE, Gordon AJ, Harris AHS (2022). Healthcare quality measures in implementation research: advantages, risks and lessons learned. [Letter to the editor]. Health Res Policy Syst, 20(1), 131. ()
    2. Kertesz SG, Varley AL, Fuqua LA, Gordon AJ (2022). The North American opioid crisis: educational failures and incautious stoppage. [Letter to the editor]. Lancet, 400(10361), 1402. ()
    3. Sowicz TJ, Gordon AJ, Gellad WF, Zhao X, Zhang H, Emmendorfer T, Good CB (2018). High Variability of Opioid Prescribing Within and Across Emergency Departments in the US Veterans Health Administration. [Letter to the editor]. J Gen Intern Med, 33(11), 1831-1832. ()
    4. Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerd M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BDL (2017). Reply to Osborne & Serdarevic (2017): Potential impact of exposure definition when examining non-medical use of prescription opioids among US veterans. [Letter to the editor]. Addiction, 112(8), 1510-1511. ()
    5. Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerda M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BD (2017). Reply to Ruan et al. (2017): Non-medical use of prescription opioids is associated with heroin initiation among US veterans. [Letter to the editor]. Addiction, 112(4), 728-729. ()
    6. Stein BD, Gordon AJ, Dick AW (2015). Buprenorphine waivers: the authors reply. [Letter to the editor]. Health Aff (Millwood), 34(8), 1428. ()
    7. Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andre T, McNicholas L (2009). Physician training is never a failure. In response and author Comment on Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration [Letter to the editor]. Am J Addict, 17(4), 337-8.
    8. Bean-Mayberry B, Gordon AJ, Fultz SL (2004). The debt repayment paradox for VA clinical investigators. [Letter to the editor]. JAMA, 291(19), 2316; author reply 2316. ()

    Abstract

    1. Narayanan AK, Saba S, Harding JH, Conley J, Gordon AJ (2016). Comparing and contrasting US national party platforms: are the two parties more aligned than different regarding official addiction related Advocacy. Addiction in pictures: homeless perspectives of addiction through photo-elicitation [Abstract]. Subst Abus, 38(1), suppl 100.
    2. Cochran G, Gordon AJ, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter R (2016). A continuum of care model for opioid misuse in community pharmacy. In: Gordon AJ. Integrating Policy and Research into Addiction Practice, AMERSA Abstracts, and an Appreciation to Our Reviewers [Abstract]. Subst Abus, 37(2), 271-5 (47A).
    3. Broyles LM, Wieland M, Confer A, Youk, Gordon A (2014). Holes in the pipeline: addressing recruitment challenges for an alcohol brief intervention trial in the acute care setting [Abstract]. Subst Abus, 35(2), 208.
    4. Becker W, Edelman EJ, Gordon KS, Kerns R, Crystal S, Fiellin LE, Gordon A, Goulet JL, Justice AC, Fiellin DA (2013). Trends and correlates of opioid analgesic receipt among Veterans with and without HIV: 1999-2010 [Abstract]. J Gen Intern Med, 28(1), S227.
    5. Kertesz S, Polli D, Holt C, Johnson-Roe K, Gordon A, Steward J, Borden A, Kim T, Stringfellow E (2012). Implications of substance abuse for primary care quality of homeless patients [Abstract]. Subst Abus, 33(2), 220-1.
    6. Gordon A, Cook R (2003). Drug and alcohol use among HIV-positive (homeless) Veterans [Abstract]. Alcohol Clin Exp Res, 27(5), 187A.
    7. Conigliaro J, McGinnis K, Gordon AJ, Rabeneck L, Briggs J, Justice AC (2002). Do providers recognize problem drinking in their HIV-positive patients? [Abstract]. J Gen Intern Med, 17(Suppl 1), 187.
    8. Kraemer KL, Maisto SA, Conigliaro J, Gordon AJ, McNeil MA, Kelley ME (2002). Health services utilization in outpatient drinkers [Abstract]. J Gen Intern Med, 17(Suppl 1), 200.
    9. Gordon AJ, Maisto SA, McNeil M, Kraemer KL, Conigliaro RL, Kelley ME, Conigliaro JC (2001). Comparison of motivational enhancement and brief advice to decrease elderly hazardous drinking behavior [Abstract]. Subst Abus, 22(2), 139.
    10. Gordon AJ, Wentz CM, Gibbon JL, Mason AD, Freyder PJ, OToole TP (1999). Relationships of patient characteristics of successful completion of substance abuse detoxification [Abstract]. J Gen Intern Med, 14(Suppl 2), 34.

    Newspaper

    1. Gordon AJ (June 9, 2006). Promote treatment. [Letter to the Editor]. Pittsburgh Post-Gazette, p. 16.
    2. Gordon AJ (January 23, 2008). The liability insurance issue threatens access to care. [Letter to the Editor]. Pittsburgh Post-Gazette, pp. B-6.
    3. Gordon AJ (September 13, 2007). No exceptions. [Letter to the Editor]. Pittsburgh Post-Gazette, pp. B-6.

    Other

    1. Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ (2019). The 2019 addiction health services research conference: Insights, review, and abstracts. Subst Abus (40(4), pp. 469-472). United States. ()
    2. Gordon AJ (2013). What not to wear: white coats (aka the coffee splotched infectious vector). Bull Allegheny County Med Soc (103(6), pp. 244-5).
    3. Gunderson EW, Gordon AJ (2011). Buprenorphine maintenance: effective care delivery in office practice. Addict Pro (9(1), pp. 30-1).
    4. Gordon A, Kertesz S, Phillips K (2011). Things you should know about buprenorphine and methadone. (34(6), pp. 7-15). Society of General Internal Medicine.
    5. Gordon AJ (2009). Clinical advocates: where are they? how can we get more? (32(2), pp. 2-11). Society of General Internal Medicine.
    6. Gordon AJ (2009). Don't say Gesundheit! when someone says SBIRT! Bull Allegheny County Med Soc (98(7), pp. 316-7).
    7. Paidisetty S, Gordon AJ (2008). Emerging medications to treat alcohol use disorders. Counter Details: The Educational Difference (pp. 10-13). Pennsylvania Medical Society.
    8. Gordon AJ (April 2008). Transparency of health care costs would benefit patients. W Penn Hosp News (p. 4).
    9. Gordon AJ (2008). How things change: a reflection of JGIM 10 years ago. (31(1), pp. 2-14). Society of General Internal Medicine.
    10. Gordon AJ (2008). Inside to outside: enabling and advocating leadership in our ever hostile environments. Bull Allegheny County Med Soc (97(1), pp. 10-11).
    11. Conroy M, Gordon A (2008). More than pierogies: Pittsburgh is perfect for SGIM. (31(3), pp. 5-6). Society of General Internal Medicine.
    12. Gordon AJ (2008). Translating research into practice: comments of recent JGIM authors. (31(3), pp. 10-12). Society of General Internal Medicine.
    13. Gordon AJ (January 2008). Make way for collaboration, integration and respect. W Penn Hosp News (pp. 1-16).
    14. Gordon AJ (2008). It's midnight: do you know where your doctor is? Bull Allegheny County Med Soc (97(4), pp. 166-7).
    15. Gordon AJ (2008). What is our message and who is listening? Bull Allegheny County Med Soc (97(2), pp. 64-5).
    16. Gordon AJ (2008). I'll write a non-peer-reviewed article any day. (31(6), pp. 2-13). Society of General Internal Medicine.
    17. Gordon AJ (2008). Research: it's not a dirty word. Bull Allegheny County Med Soc (97(7), pp. 268-9).
    18. Gordon AJ (2008). Click. Bull Allegheny County Med Soc (97(8), pp. 362-98).
    19. Gordon AJ (July 2008). The Allegheny County Medical Society: where we have been is not where are we are going. Hosp News (p. 8).
    20. Gordon AJ (2008). Looking forward - thinking about the past. Bull Allegheny County Med Soc (97(9), pp. 408-9).
    21. Gordon AJ (2008). Click. (31(10), pp. 4-12). Society of General Internal Medicine.
    22. Gordon AJ (2008). Staying alive – physicians must take care of patients and business. Dynamic Business (63(7), pp. 10-11).
    23. Gordon AJ (2008). Health care crisis: understand, advocate, vote. Bull Allegheny County Med Soc (31(10), pp. 458-9).
    24. Gordon AJ (2008). Change and charge: reflections of the year. Bull Allegheny County Med Soc (97(12), pp. 552-3).
    25. Gordon AJ (2007). Big Brother is watching us: computers impact doctor-patient interactions. (30(1), pp. 7-13). Society of General Internal Medicine.
    26. Gordon AJ (2007). A purulent presentation of Proteus pericarditis in Pittsburgh. (30(2), p. 12). Society of General Internal Medicine.
    27. Gordon AJ, Conroy MB (2007). Japanese medicine: a contrast to Pittsburgh's medical environment. Bull Allegheny County Med Soc (96(4), pp. 174-7).
    28. Gordon AJ (2007). Chronic benzodiazepine use: evaluating impact on the elderly. (30(8), p. 6). Society of General Internal Medicine.
    29. Gordon AJ (2007). Life chaos: impacts on health and health care utilization. (30(9), pp. 2-13). Society of General Internal Medicine.
    30. Gordon AJ (2007). Modeling the way: time to train physician leaders. Bull Allegheny County Med Soc (96(11), pp. 496-7).
    31. Gordon AJ (2006). Buprenorphine: a novel medication in novel environments to treat opioid dependence. Counter Details: The Educational Difference (pp. 2-5). Pennsylvania Medical Society.
    32. Gordon AJ (2006). Balloons and stamp bags: new possibilities for opioid dependence treatment. Counter Details: The Educational Difference (pp. 7-8). Pennsylvania Medical Society.
    33. Gordon AJ (2006). Alcohol and drug use in women: important HIV risks. Counter Details: The Educational Difference (pp. 9-10). Pennsylvania Medical Society.
    34. Gordon AJ (2006). Assessing pain: practice outcomes before and after a system intervention. (29(6), p. 5). Society of General Internal Medicine.
    35. Gordon AJ (2006). Patients' perspectives on disclosing medical errors. (29(7), pp. 5-9). Society of General Internal Medicine.
    36. Gordon AJ (2006). Fueling the fire for change: research explores the implications of work hour regulations on graduate medical education. (29(9), pp. 1-8). Society of General Internal Medicine.
    37. Gordon AJ (2006). Inequity among us: salaries of internists differ based on race and gender. (29(11), p. 4). Society of General Internal Medicine.
    38. Gordon AJ (2006). Tickling the keyboard: older adults and the Internet. (29(12), pp. 6-9). Society of General Internal Medicine.
    39. Walbrown MA, Gordon AJ (2006). Treating alcohol drinking: new medications to curb consumption. Bull Allegheny County Med Soc (95(1), pp. 24-7).
    40. Gordon AJ (2006). The new bottom line: money not patients. Bull Allegheny County Med Soc (95(4), pp. 170-1).
    41. Gordon AJ (2006). Integrating mental health into primary care: innovation and application. (29(1), pp. 4-10). Society of General Internal Medicine.
    42. Gordon AJ (2006). Promotion of clinical educators and investigators in academic medicine. (29(2), pp. 4-9). Society of General Internal Medicine.
    43. Gordon AJ (2006). ACLS skills: evaluating residents' performance through simulated scenarios. (29(3), pp. 5-9). Society of General Internal Medicine.
    44. Gordon AJ (2005). Attitudes toward race and ethnicity data collection. (28(10), p. 7). Society of General Internal Medicine.
    45. Gordon AJ (2005). Interpreters, language concordant clinicians, and health care quality. (28(11), p. 7). Society of General Internal Medicine.
    46. Gordon AJ (2005). Is your doctor watching your weight? (28(12), pp. 1-9). Society of General Internal Medicine.
    47. Montlack ML, Gordon AJ, Williams J (2005). Integration of services in homeless health care. Bull Allegheny County Med Soc (94(8), pp. 392-5).
    48. Gaglia MA Jr, Gordon AJ (2005). For the birds: pandemic influenza policy falls short. Bull Allegheny County Med Soc (94(12), pp. 606-7).
    49. Gordon AJ, Salmon-Cox S (2004). Treatment for opiate addiction in outpatient settings. Bull Allegheny County Med Soc (92(5), pp. 228-31).
    50. Gordon AJ (2004). Never "clear" anyone for surgery: the role of medical consultation. Bull Allegheny County Med Soc (93(8), pp. 403-9).
    51. Gordon AJ (2004). Improving patient safety: the physician pinch. Bull Allegheny County Med Soc (93(11), pp. 528-31).
    52. Montlack M, Gordon AJ (2004). Too much nog? recommendations for safe drinking this holiday season. Bull Allegheny County Med Soc (93(11), pp. 552-5).
    53. Gordon AJ (2003). Shape your future: going beyond the patient-physician relationship. Bull Allegheny County Med Soc (92(4), pp. 187-9).
    54. Gordon AJ (2000). Exploration of alternative treatment settings of alcohol detoxification. [Master's Thesis]. Pittsburgh, PA: 㽶Ƶ of Pittsburgh Press.

    Report

    1. Donohue JM, Lo-Ciganic Wei-Hsuan, Cochran G, Gordon AJ, Zemaitis MA, Gellad WF (December 2013). Preliminary report on opioid use, opioid use disorder and buprenorphine use in Pennsylvania Medicaid. Report to the Commonwealth of Pennsylvania’s Department of Health.
    2. VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives, Gordon A, Kivlahan D, Liberto J, McNicholas L, Oslin D, Saxon A, Trafton J (April 2013). Criteria for Use of Buprenorphine/Naloxone and Buprenorphine Sublingual Tablets. Criteria for Use Monograph, Washington, DC: U.S. Department of Veterans Affairs.
    3. Goodman F, Gordon A, Kivlahan D, Dalack G, McNicholas L, Oslin D, Saxon A, Suchinsky R, for the VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel (2009). Criteria for Use of Buprenorphine/Naloxone and Buprenorphine Sublingual Tablets. Criteria for Use Monograph, Washington, DC: U.S. Department of Veterans Affairs.
    4. Goodman F, Gordon A, Kivlahan D, Dalack G, Pope J, McNicholas L, Suchinsky R, Veterans Health Administration Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel (2003). Criteria for Non-formulary Use of Buprenorphine Sublingual Tablets for Opioid Dependence. Criteria for Use Monograph, Washington, DC: U.S. Department of Veterans Affairs.

    Video/Film/CD/Web/Podcast

    1. The Management of Substance Use Disorders Working Group (2015). VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders [Version 3.0] [Web]. U.S. Department of Veterans Affairs and U.S. Department of Defense. Available: https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGFinal1.pdf.
    2. Comer S, Cunningham C, Fishman MJ, Gordon AJ, Kampman K, Langleben D, Nordstrom B, Oslin D, Woody G, Wright T, Wyatt S (2015). The National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use [Web]. American Society of Addiction Medicine. Available: https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf.
    3. Olstein J, Gordon AJ, Conigliaro J (revised 2009, 2011). Identification and management of alcohol use disorders in the perioperative period [Web]. Wellesley, MA: UpToDate. Available: https://www.uptodate.com/contents/identification-and-management-of-unhealthy-alcohol-use-in-the-perioperative-period.
    4. Gordon AJ (2010). PCSS-B Guidance: The Off-label Use of Sublingual Buprenorphine and Buprenorphine/naloxone for Pain [Web]. Providers’ Clinical Support System for Medication-Assisted Treatment. Available: https://pcssnow.org/wp-content/uploads/2014/02/PCSS-MATGuidanceOff-label-bup-for-pain.Gordon.pdf.
    5. The Management of Substance Use Disorders Working Group (2009). VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders [Version 2.0 – 2009] [Web]. U.S. Department of Veterans Affairs and the U.S. Department of Defense. Available: https://www.healthquality.va.gov/guidelines/MH/sud/sud_sum_6_1.pdf.
    6. Gordon AJ (2009). Models of Care and Office Management of Buprenorphine for the Treatment of Opioid Dependence [Web]. American Society of Addiction Medicine. Available: http://www.opioiddependencetxcme.com.
    7. Gordon AJ (July 2008). Dependence vs. Pain. [Commentary] [Web]. Agency for Healthcare Research and Quality WebM&M. Available: https://psnet.ahrq.gov/webmm/case/179/Dependence-vs-Pain-.